Form 10-Q - Quarterly report [Sections 13 or 15(d)]

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

		(Mark One)
x		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

OR

¨

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number 001-41171

 

AULT DISRUPTIVE TECHNOLOGIES CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

Delaware	86-2279256
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

 

11411 Southern Highlands Pkwy, Suite 240, Las Vegas, NV	89141	[phone]
(Address of principal executive offices)	(Zip Code)	(Registrant’s telephone number, including area code)

 

Securities registered under Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Units, each consisting of one share of common stock, par value $0.001 per share and three-fourths of one redeemable warrant to purchase one share of common stock		ADRU		NYSE American
Common stock, $0.001 par value		ADRT		NYSE American

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x   No  ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated Filer	x	Smaller reporting company	x
		Emerging growth company	x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes x    No  ¨

 

As of August 16, 2024, there were 2,942,180 outstanding shares of the registrant’s common stock, $0.001 par value per share, of which 67,180 shares are subject to possible redemption.

 

 

 

 

AULT DISRUPTIVE TECHNOLOGIES CORPORATION

Quarterly Report on Form 10-Q

Table of Contents

 

PART I. FINANCIAL INFORMATION			1
Item 1.	Condensed Financial Statements		1
	Condensed Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023		1
	Condensed Statements of Operations for the three and six months ended June 30, 2024 and June 30, 2023 (Unaudited)		2
	Condensed Statement of Changes in Stockholders’ Deficit for the three and six months ended June 30, 2024 and June 30, 2023 (Unaudited)		3
	Condensed Statements of Cash Flows for the six months ended June 30, 2024 and June 30, 2023 (Unaudited)		4
	Notes to Unaudited Condensed Financial Statements		5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		23
Item 4.	Controls and Procedures		23
PART II. OTHER INFORMATION			24
Item 1.	Legal Proceedings		24
Item 1A.	Risk Factors		24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		24
Item 3.	Defaults Upon Senior Securities		24
Item 4.	Mine Safety Disclosures		24
Item 5.	Other Information		24
Item 6.	Exhibits		25
SIGNATURES			26

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

AULT DISRUPTIVE TECHNOLOGIES CORPORATION

BALANCE SHEETS

		June 30, 2024				December 31, 2023
Assets		(Unaudited)
Current assets:
Cash		$	866			$	163,235
Prepaid expenses			42,500				10,873
Total current assets			43,366				174,108
Cash and marketable securities held in the trust account (the “Trust Account”)			794,122				2,200,308
Deferred tax asset, noncurrent			9,446				-
Total Assets		$	846,934			$	2,374,416
Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable		$	423,045			$	256,937
Accrued expenses			66,834				48,985
Accrued excise tax			1,214,906				1,200,638
Income tax payable			3,393				132,353
Related party note payable			950,681				550,383
Total current liabilities			2,658,859				2,189,296
Deferred underwriting commissions			3,450,000				3,450,000
Total liabilities			6,108,859				5,639,296
Commitments
Common stock subject to possible redemption, 67,180 shares and 188,875 shares at redemption value as of June 30, 2024 and December 31, 2023, respectively(1)			794,845				2,201,557
Stockholders’ Deficit:
Preferred stock, $0.001 par value; 1,000,000 shares authorized; none issued and outstanding			-				-
Common stock, $0.001 par value; 100,000,000 shares authorized; 2,875,000 shares issued and outstanding (excluding 67,180 and 188,875 shares subject to possible redemption) as of June 30, 2024 and December 31, 2023, respectively			2,875				2,875
Accumulated deficit			(6,059,645	)			(5,469,312	)
Total stockholders’ deficit			(6,056,770	)			(5,466,437	)
Total Liabilities, Commitments and Stockholders’ Deficit		$	846,934			$	2,374,416

 

(1)

Redemption value is net of amounts eligible to be withdrawn from the Trust Account to pay franchise and income taxes.

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

1

 

AULT DISRUPTIVE TECHNOLOGIES CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2024				2023				2024				2023
Operating costs		$	239,040			$	455,964			$	553,998			$	814,852
Loss from operations			(239,040	)			(455,964	)			(553,998	)			(814,852	)
Other income:
Income from investments held in the Trust Account			10,219				1,279,341				31,182				2,532,744
Interest expense, net			(21,812	)			-				(37,870	)			-
Total other (loss) income, net			(11,593	)			1,279,341				(6,688	)			2,532,744
Net (loss) income before income taxes			(250,633	)			823,377				(560,686	)			1,717,892
Provision for income taxes			(4,481	)			298,033				(4,723	)			636,876
Net (loss) income		$	(246,152	)		$	525,344			$	(555,963	)		$	1,081,016
Basic and diluted weighted average shares outstanding, common stock subject to redemption			67,180				10,505,615				101,281				11,000,061
Basic and diluted net (loss) income per share attributable to common stock subject to redemption		$	(0.08	)		$	0.04			$	(0.19	)		$	0.08
Basic and diluted weighted average shares outstanding, common stock			2,875,000				2,875,000				2,875,000				2,875,000
Basic and diluted net (loss) income per share attributable to common stockholders		$	(0.08	)		$	0.04			$	(0.19	)		$	0.08

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

2

 

AULT DISRUPTIVE TECHNOLOGIES CORPORATION

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT FOR THE

SIX MONTHS ENDED JUNE 30, 2024 AND 2023

(Unaudited)

		Common Stock Shares				Common Stock Amount				Additional Paid-in Capital				Accumulated Deficit				Total Stockholders’ Deficit
Balance as of January 1, 2024			2,875,000			$	2,875			$	-			$	(5,469,312	)		$	(5,466,437	)
Remeasurement adjustment on redeemable common stock, net(1)			-				-				-				(15,145	)			(15,145	)
Excise tax imposed on common stock redemptions															(14,268	)			(14,268	)
Net loss			-				-								(309,811	)			(309,811	)
Balance as of March 31, 2024			2,875,000				2,875				-				(5,808,536	)			(5,805,661	)
Remeasurement adjustment on redeemable common stock, net(1)			-				-				-				(4,957	)			(4,957	)
Net loss			-				-				-				(246,152	)			(246,152	)
Balance as of June 30, 2024			2,875,000			$	2,875			$	-			$	(6,059,645	)		$	(6,056,770	)

 

(1)

Remeasurement adjustment is net of amounts eligible to be withdrawn from the Trust Account to pay franchise and income taxes for the period.

 

 

		Common Stock Shares				Common Stock Amount				Additional Paid-in Capital				Accumulated Deficit				Total Stockholders’ Deficit
Balance as of January 1, 2023			2,875,000			$	2,875			$	-			$	(2,969,983	)		$	(2,967,108	)
Remeasurement adjustment on redeemable common stock, net(1)			-				-				-				(872,023	)			(872,023	)
Net income			-				-								555,672				555,672
Balance as of March 31, 2023			2,875,000				2,875				-				(3,286,334	)			(3,283,459	)
Remeasurement adjustment on redeemable common stock, net(1)			-				-				-				(1,010,609	)			(1,010,609	)
Excise tax imposed on common stock redemptions			-				-								(1,200,638	)			(1,200,638	)
Net income			-				-				-				525,344				525,344
Balance as of June 30, 2023			2,875,000			$	2,875			$	-			$	(4,972,236	)		$	(4,969,361	)

 

(1)

Remeasurement adjustment is net of amounts eligible to be withdrawn from the Trust Account to pay franchise and income taxes for the period.

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

3

 

AULT DISRUPTIVE TECHNOLOGIES CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

		For the Six Months Ended June 30,
		2024				2023
Cash flows from operating activities:
Net (loss) income		$	(555,963	)		$	1,081,016
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Income from investments held in the Trust Account			(31,182	)			(2,532,744	)
Changes in current assets and current liabilities:
Prepaid expenses			(31,627	)			195,721
Accounts payable			166,108				439,808
Accrued expenses			17,849				(156,381	)
Income tax payable			(138,406	)			397,876
Net cash used in operating activities			(573,221	)			(574,704	)
Cash flows from investing activities:
Cash withdrawn from the Trust Account for tax obligations			10,554				851,339
Extension payments deposited into the Trust Account							(2,300,000	)
Extension fee interest payments deposited into the Trust Account							(31,995	)
Cash withdrawn from the Trust Account in connection with redemptions			1,426,814				120,063,828
Net cash provided by investing activities			1,437,368				118,583,172
Cash flows from financing activities:
Proceeds from related party notes payable			400,298				-
Proceeds from extension fees							2,300,000
Proceeds from extension fee interest earned							31,995
Payment from the Trust Account in connection with redemptions			(1,426,814	)			(120,063,828	)
Net cash used in financing activities			(1,026,516	)			(117,731,833	)
Net change in cash			(162,369	)			276,635
Cash, beginning of the period			163,235				206,527
Cash, end of the period		$	866			$	483,162
Supplemental non-cash investing and financing activities:
Excise tax liability arising from redemption of common stock		$	14,268			$	1,200,638
Remeasurement of common stock subject to possible redemption		$	20,102			$	1,882,632

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

4

 

AULT DISRUPTIVE TECHNOLOGIES CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

 

Note 1 — Organization and Business Operations

 

Organization

 

Ault Disruptive Technologies Corporation (the “Company,” “ADRT,” “we,” or “our”) is a blank check company organized on February 22, 2021, under the laws of the State of Delaware. The Company was formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities (“initial business combination”).

 

As of June 30, 2024, the Company had not commenced any operations. All activity for the period from February 22, 2021 through June 30, 2024, related to the Company’s formation, the initial public offering (“IPO” or “Public Offering”) described below and the search for an initial business combination. The Company will not generate any operating revenues until after the completion of its initial business combination, at the earliest. The Company will generate nonoperating income in the form of interest income on cash and cash equivalents from the proceeds derived from the IPO and the sale of the Private Placement Warrants (as defined below). The Company has selected December 31 as its fiscal year end.

 

The Company’s sponsor is Ault Disruptive Technologies Company, LLC, a Delaware limited liability company (the “Sponsor”), which is a wholly owned subsidiary of Ault Alliance, Inc., a Delaware corporation (NYSE American: AULT) (“Ault”).

 

Financing 

 

The registration statement for the Company’s IPO was declared effective on December 15, 2021 (the “Effective Date”). On December 20, 2021, the Company consummated its IPO of 10,000,000 units at $10.00 per unit (the “Units”), which is discussed in Note 3. Each Unit consists of one share of common stock, par value $0.001 per share and three-fourths of one redeemable warrant (the “Public Warrants”). Each whole Public Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share. On December 20, 2021, the underwriters exercised their full over-allotment option and purchased the additional Units available to them. The aggregate Units sold in the IPO and subsequent over-allotment were 11,500,000 and generated gross proceeds of $115,000,000. 

 

Simultaneously with the consummation of the IPO, the Company consummated the private placement of 6,500,000 warrants (7,100,000 warrants when the underwriters’ over-allotment option was fully exercised on December 20, 2021) (the “Private Placement Warrants”), at a price of $1.00 per Private Placement Warrant in a private placement. The sale of the Private Placement Warrants in connection with the IPO and subsequent over-allotment option exercise generated gross proceeds of $7,100,000. 

 

Transaction costs related to the IPO amounted to $6,297,333 consisting of $2,513,333 of underwriting commissions, $3,000,000 of deferred underwriting commissions, and $784,000 of other offering costs. The underwriters’ exercise of their full over-allotment option generated an additional $825,000 in transaction costs for aggregate transaction costs of $7,122,333 consisting of $2,888,333 of underwriting commissions, $3,450,000 of deferred underwriting commissions and $784,000 of other offering costs. In addition, $1,849,679 of cash was held outside of the Trust Account (as defined below) and used for working capital purposes.

 

Initial Business Combination

 

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating the initial business combination.

 

The Company must complete one or more initial business combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the interest earned in the Trust Account) at the time of signing a definitive agreement in connection with the initial business combination. However, the Company will complete the initial business combination only if the post-business combination company in which its public stockholders own shares will own or acquire 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to complete a business combination successfully or on a timely basis.

 

On December 13, 2022, the Company received notice from the Sponsor of the Sponsor’s intention to deposit $1,150,000 into the Trust Account established in connection with the Company’s initial public offering (the “First Deposit”). The First Deposit was required to extend the period of time the Company will have to consummate its initial business combination by three months from the initial deadline of December 20, 2022 until March 20, 2023. When the Sponsor made the First Deposit, it received 1,150,000 Private Placement Warrants.

 

5

 

On June 1, 2023, the Sponsor made deposit payments totaling $2,331,995, including $31,995 of interest, for previously elected extensions of the period the Company had to consummate its initial business combination by six months from the initial deadline of December 20, 2022, until June 20, 2023, and received 2,300,000 Private Placement Warrants. The Company’s Sponsor currently holds 9,400,000 Private Placement Warrants (consisting of the private placement of 6,500,000 warrants upon consummation of the IPO, the underwriters’ over-allotment option of 600,000 that was fully exercised on December 20, 2021, and the required outstanding deposit payment of $2,300,000 to purchase 2,300,000 Private Placement Warrants, related to the Company’s extension of the time it had to consummate the initial business combination).

 

On June 15, 2023, the Company held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders approved two proposals amending the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to (i) extend the date by which the Company must complete an initial business combination from June 20, 2023 to September 20, 2023 (“Charter Extension Date”) and to allow the Company, without another stockholder vote, to elect to extend the Charter Extension Date to consummate an initial business combination on a monthly basis up to five times by an additional one month each time after September 20, 2023, upon the request by the Sponsor, and approval by the Company’s board of directors until February 20, 2024 or a total of up to eight months, unless the closing of an initial business combination shall have occurred prior thereto and (ii) delete (a) the limitation that the Company shall not consummate an initial business combination if it would cause the Company’s net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (or any successor rule)) to be less than $5,000,0001 following such redemptions and (b) the limitation that the Company shall not redeem public shares that would cause the Company’s net tangible assets to be less than $5,000,001 following such redemptions (collectively, the “Charter Amendment”).

 

On February 15, 2024, the Company held a special meeting of stockholders (the “Second Special Meeting”). At the Second Special Meeting, a proposal to amend the Certificate of Incorporation to extend the Termination Date by which the Company must consummate a business combination from February 20, 2024 to December 20, 2024 (the date that is 36 months from the closing date of the IPO) (the “Termination Date”) was passed.

 

Trust Account

 

Following the closing of the IPO on December 20, 2021, $116,725,000 from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was deposited into the Trust Account. This amount was comprised of $10.15 per Unit for the 11,500,000 Units sold in the IPO. Following the closing of the IPO and the exercise of the underwriters’ full over-allotment option, $116,725,000 was held in the Trust Account and will only be invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act, which invest only in direct U.S. government treasury obligations. Pursuant to the trust agreement, the trustee is not permitted to invest in other securities or assets. By restricting the investment of the proceeds to these instruments, and by having a business plan targeted at acquiring and growing businesses for the long term (rather than buying and selling businesses in the manner of a merchant bank or private equity fund), the Company intends to avoid being deemed an “investment company” within the meaning of the Investment Company Act. The Trust Account is intended as a holding place for funds pending the earliest to occur of: (i) the consummation of the Company's initial business combination; (ii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend its amended and restated certificate of incorporation (A) to modify the substance or timing of its obligation to allow redemptions in connection with the Company's initial business combination or certain amendments to its charter prior thereto or to redeem 100% of the Company's public shares if the Company does not consummate its initial business combination by the Termination Date or (B) with respect to any other provision relating to stockholders' rights or pre-initial business combination activity; or (iii) absent an initial business combination by the Termination Date, the Company's return of the funds held in the Trust Account to its public stockholders as part of its redemption of the public shares.

 

If the Company is unable to consummate its initial business combination, the Company's public stockholders may receive only approximately $10.35 per public share on the liquidation of the Trust Account and its Public Warrants will expire worthless.

 

The Company will provide holders (the “Public Stockholders”) of its common stock sold in the IPO (the “Public Shares”), with the opportunity to redeem all or a portion of their Public Shares upon the completion of a business combination either (i) in connection with a general meeting called to approve the business combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed business combination or conduct a tender offer will be made by the Company, solely at its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek stockholder approval under applicable law or stock exchange listing requirement.

 

The Company will provide its Public Stockholders with the opportunity to redeem all or a portion of their common stock upon the completion of the initial business combination, regardless of whether such stockholder votes on such proposed business combination, and if they do vote, regardless of whether they vote for or against such proposed business combination, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial business combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then-outstanding public shares, subject to the limitations described herein. The amount in the Trust Account is currently anticipated to be $10.35 per public share.

 

6

 

The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters. The redemption rights will include the requirement that a beneficial holder must identify itself in order to validly redeem its shares. There will be no redemption rights upon the completion of the initial business combination with respect to the Company’s warrants. Further, the Company will not proceed with redeeming the Public Shares, even if a Public Stockholders has properly elected to redeem its shares if a business combination does not close. 

 

All common stock subject to redemption was recorded at a redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity (“ASC Topic 480”). The Company will proceed with a business combination if the Company seeks stockholder approval and a majority of the issued and outstanding shares cast are voted in favor of the business combination. Following the Second Special Meeting, the Company’s Certificate of Incorporation provides that the Company will have until the Termination Date to consummate its initial business combination. If the Company has not consummated an initial business combination by the Termination Date, the Company will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income taxes, if any (less up to $50,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably practicable following such redemption, subject to the approval of the Company’s remaining stockholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to consummate an initial business combination by the Termination Date.

 

The Sponsor and each member of its management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares (defined in Note 7), Private Placement Warrants and Public Shares held by them (ii) to waive their redemption rights with respect to their Founder Shares, Private Placement Warrants and Public Shares in connection with a stockholder vote to approve an amendment to the Company’s Certificate of Incorporation (A) that would modify the substance or timing of the Company’s obligation to provide holders of shares of common stock the right to have their shares redeemed in connection with the initial business combination or to redeem 100% of the public shares if the Company does not complete the initial business combination by the Termination Date or (B) with respect to any other provision relating to the rights of holders of shares of common stock or pre-initial business combination activity and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares and Private Placement Warrants they hold if the Company fails to consummate an initial business combination by the Termination Date (although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete the initial business combination within the prescribed time frame).

 

The Sponsor has agreed to waive its liquidation rights with respect to the Founder Shares and Private Placement Warrants if the Company fails to consummate a business combination by the Termination Date. However, if the Sponsor acquires Public Shares in or after the Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to consummate a business combination by the Termination Date. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) in the event the Company does not consummate a business combination by the Termination Date and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Public Offering price per Unit ($10.35 per Public Share). 

 

In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written confidentiality or similar agreement, letter of intent, or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (1) $10.35 per public share, and (2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay the Company’s taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses, or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

 

7

 

Merger Agreement

 

On June 23, 2024, ADRT entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) by and among ADRT, ADRT Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of ADRT (“Merger Sub”), and Gresham Worldwide, Inc., a California corporation (“Gresham”). The transactions contemplated by the Merger Agreement are referred to herein as the “Business Combination.”

 

Pursuant to the Merger Agreement and subject to the terms and conditions set forth therein, the Merger Sub was intended to merge with and into Gresham (the “Merger”), with Gresham being the surviving corporation and thereby becoming a wholly owned subsidiary of ADRT. Upon the Closing of the Business Combination (the “Effective Time”), it was expected that ADRT would be renamed Gresham Worldwide, Inc., and thereafter remain listed on the NYSE American under a new ticker symbol, “GWWI.”

 

While each of ADRT and Gresham is a publicly traded corporation, Ault beneficially owns a majority of each of ADRT’s and Gresham’s shares of common stock and the Boards of Directors of Ault, ADRT and Gresham consist of several identical members. As such, the Business Combination is a related party transaction.

 

The Merger Agreement and the transactions contemplated thereby were unanimously approved by the board of directors of ADRT and Gresham. The Business Combination was targeted to be consummated in the fourth quarter of 2024, after receipt of the required approval by the stockholders of ADRT, the required approval of the shareholders of Gresham and the fulfilment of certain other terms and conditions set forth in the Merger Agreement.

 

However, on August 14, 2024, Gresham filed a petition for reorganization under Chapter XI of the bankruptcy laws. Consequently, ADRT was required to terminate the Merger Agreement, which it did on August 15, 2024.  It is uncertain whether we will enter into a new agreement and plan of merger with a third party.

 

Liquidity and Going Concern

 

As of June 30, 2024, the Company had cash of $866 held outside of the Trust Account and a working capital deficit of $2,615,493. As of June 30, 2024, the Company had marketable securities held in the Trust Account of approximately $794,122, consisting of U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended, which invest only in direct U.S. government treasury obligations. Investment and interest income on the balance in the Trust Account may be used by the Company to pay taxes. During the three months and six months ended June 30, 2024, $10,219 and $31,182, respectively, of income from investments held in the Trust Account was earned.

  

In order to finance transaction costs in connection with the initial business combination, our Sponsor or an affiliate of the Sponsor, or certain of our officers and directors may, but are not obligated to, provide us with funds as may be required (“Working Capital Loans”). We may need to raise additional capital through loans or additional investments from our Sponsor, stockholders, officers, directors, or third parties. Our officers, directors and our Sponsor may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet our working capital needs. Accordingly, we may not be able to obtain additional financing. If we are unable to raise additional capital, we may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. We cannot provide any assurance that new financing will be available to us on commercially acceptable terms, if at all. We will provide our public stockholders with the opportunity to redeem all or a portion of their shares of our common stock upon the consummation of our initial business combination, subject to the limitations described herein.

 

It is uncertain whether we will be able to consummate an initial business combination by December 20, 2024 or obtain working capital loans from the Sponsor. If an initial business combination is not consummated by the required date pursuant to the rules of the NYSE American, there will be a mandatory liquidation and subsequent dissolution, presuming that the Company remains listed on the NYSE American. In the event of a dissolution, we anticipate a shortfall of liquidity. Our anticipated shortfall of sufficient liquidity to meet our current and future estimated financial obligations raises substantial doubt about our ability to continue as a going concern for a period of time within one year after the date that the accompanying financial statements are issued. We plan to address this uncertainty through working capital loans. There is no assurance that working capital loans will be available to us or that any plans to consummate an initial business combination will be successful.

 

Risks and Uncertainties

 

The Company has a limited operating history and has not yet generated revenue from intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including but not limited to, credit risk, changes to regulations governing the Company’s industry, and the outbreak or escalation of wars including, but not limited to, conflicts between Russia and Ukraine and between Israel and Hamas and other groups or states in the region, and the relationship between China and the U.S. Adverse developments in these general business and economic conditions could have a material adverse effect on the Company’s financial condition and the results of its operations.

 

8

 

Inflation Reduction Act of 2022

 

On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its stockholder from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.

 

On December 27, 2022, the Treasury released Notice 2023-2, which provides taxpayers with interim guidance on the excise tax that may be relied upon until the Internal Revenue Service issues proposed Treasury regulations on such matter. Notice 2023-2 includes as one of its exceptions to the excise tax a distribution in complete liquidation of a “covered corporation”, such as ours, to which Sec. 331 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), applies (so long as Sec. 332(a) of the Code also does not also apply). Although it remains uncertain whether, and/or to what extent, the excise tax could apply to any redemptions of our public shares after December 31, 2022, including any redemptions in connection with our initial business combination or in the event we do not consummate our initial business combination by the Termination Date, we would not expect the excise tax to apply to redemptions of our public shares that occur during a taxable year in which we completely liquidate under Sec. 331 of the Code.

 

Any redemption or other repurchase that occurs after December 31, 2022 may be subject to the excise tax, including in connection with our initial business combination, certain amendments to our charter or otherwise. Whether and to what extent we would be subject to the excise tax would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the initial business combination, certain amendments to our charter or otherwise, (ii) the structure of the initial business combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with the initial business combination (or otherwise issued not in connection with the initial business combination but issued within the same taxable year of the initial business combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by us and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete our initial business combination and in our ability to complete our initial business combination. As of December 31, 2023, we recognized approximately $1,200,638 in excise tax payable related to share redemptions. During the three months ended March 31, 2024, we recognized an additional $14,268 in excise tax payable related to share redemptions of 121,695 shares. As of June 30, 2024, the Company has recognized $1,214,906 in excise tax payable.

 

Note 2 — Basis of Presentation and Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). 

 

Emerging Growth Company Status

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. 

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non- emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.  

 

9

 

Use of Estimates

 

The preparation of the financial statements is in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

 

Common Stock Subject to Redemption

 

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480. Common stock subject to mandatory redemption (if any) will be classified as a liability instrument and measured at fair value. Conditionally redeemable shares of common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) will be classified as temporary equity. At all other times shares of common stock will be classified as stockholders’ equity. The Company’s common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, 67,180 shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet at June 30, 2024.

 

The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of the shares of common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable shares of common stock are affected by charges against additional paid in capital or accumulated deficit if additional paid in capital is zero.

 

As of June 30, 2024 and December 31, 2023, the shares of common stock reflected in the condensed balance sheets are reconciled in the following table:

Common stock subject to possible redemption as of December 31, 2023		$	2,201,557
Less:
Redemptions of common stock			(1,426,814	)
Plus:
Remeasurement of carrying value to redemption value			15,145
Common stock subject to possible redemption as of March 31, 2024			789,888
Plus:
Remeasurement of carrying value to redemption value			4,957
Common stock subject to possible redemption as of June 30, 2024		$	794,845

 

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $866 and $163,235 in cash and no cash equivalents as of June 30, 2024 and December 31, 2023, respectively. As of June 30, 2024, there were no amounts yet to be remitted to tax authorities. As of December 31, 2023, $157,339 had yet to be remitted to tax authorities.

 

Marketable Securities Held in the Trust Account

 

At June 30, 2024 and December 31, 2023, funds held in the Trust Account included $794,122 and $2,200,308, respectively, of investments held in a money market fund characterized as Level 1 investments within the fair value hierarchy under ASC Topic 820 (as defined below). The funds were invested in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts.

 

10

 

Fair Value of Financial Instruments

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC Topic 820, Fair Value Measurements and Disclosures (“ASC Topic 820”), approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.

 

Offering Costs Associated with the IPO

 

The Company complies with the requirements of ASC Topic 340-10-S99-1, Other Assets and Deferred Costs, and SEC Staff Accounting Bulletin (“SAB”) Topic 5A, Expenses of Offering. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the IPO. Offering costs associated with warrants and shares of common stock not subject to redemption are charged to stockholders’ deficit. The Company incurred offering costs amounting to $6,297,333, consisting of $2,513,333 of underwriting commissions, $3,000,000 of deferred underwriting commissions, and $784,000 of other offering costs. The underwriters’ exercise of their full over-allotment option generated an additional $825,000 in transaction costs for aggregate transaction costs of $7,122,333, consisting of $2,888,333 of underwriting commissions, $3,450,000 of deferred underwriting commissions and $784,000 of other offering costs.

 

Warrant Instruments

 

The Company accounted for the 8,625,000 Public Warrants and the 9,400,000 Private Placement Warrants issued in connection with the IPO and Private Placement in accordance with the guidance contained in ASC Topic 480 and ASC Topic 815, Derivatives and Hedging, (“ASC Topic 815”). The assessment considered whether the instruments are freestanding financial instruments pursuant to ASC Topic 480, meet the definition of a liability pursuant to ASC Topic 480, or whether the instruments meet all of the requirements for equity classification under ASC Topic 815, including whether the instruments are indexed to the Company’s own common stock and whether the holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, as well as other conditions, for equity classification. The Public and Private Placement Warrants met the criteria for equity classification. 

 

Net (Loss) Income per Share of Common Stock

 

We comply with the accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share. Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. Remeasurement associated with the redeemable shares of common stock is excluded from net loss per share as the redemption value approximates fair value. At June 30, 2024 and 2023, we did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into shares of common stock and then share in our earnings. As a result, diluted loss per share is the same as basic loss per share for the periods presented.

 

The following table reflects the calculation of basic and diluted net loss per common share:

		For the Three Months Ended June 30, 2024								For the Six Months Ended June 30, 2024
		Common Stock Subject to Redemption				Non- Redeemable Common Stock				Common Stock Subject to Redemption				Non- Redeemable Common Stock
Basic and diluted net loss per share of common stock
Numerator:
Allocation of net loss		$	(5,620	)		$	(240,532	)		$	(18,819	)		$	(537,044	)
Denominator:
Basic and diluted weighted average shares outstanding			67,180				2,875,000				101,281				2,875,000
Basic and diluted net loss per share of common stock		$	(0.08	)		$	(0.08	)		$	(0.19	)		$	(0.19	)

 

11

 

The following table reflects the calculation of basic and diluted net income per common share:

 

		For the Three Months Ended June 30, 2023								For the Six Months Ended June 30, 2023
		Common Stock Subject to Redemption				Non- Redeemable Common Stock				Common Stock Subject to Redemption				Non- Redeemable Common Stock
Basic and diluted net income per share of common stock
Numerator:
Allocation of net income		$	412,467			$	112,877			$	857,023			$	223,993
Denominator:
Basic and diluted weighted average shares outstanding			10,505,615				2,875,000				11,000,061				2,875,000
Basic and diluted net income per share of common stock		$	0.04			$	0.04			$	0.08			$	0.08

 

Income Taxes

 

The Company calculates its interim income tax provision in accordance with ASC Topic 270, Interim Reporting, and ASC Topic 740, Income Taxes (“ASC Topic 740”). The Company’s effective tax rate (“ETR”) from operations was 1.2% and 0.8% for the three and six months ended June 30, 2024, respectively, and 36% and 37% for the three and six months ended June 30, 2023, respectively. The Company recorded an income tax benefit of ($4,481) and ($4,723) for the three and six months ended June 30, 2024, respectively, and income tax expense of $298,033 and $636,876 for the three and six months ended June 30, 2023, respectively. The difference between the ETR and federal statutory rate of 21.0% is primarily attributable to a U.S. federal valuation allowance.

 

A valuation allowance is recorded when it is more-likely-than-not some of the Company’s deferred tax assets may not be realized. Significant judgment is applied when assessing the need for a valuation allowance and the Company considers future taxable income, reversals of existing deferred tax assets and liabilities and ongoing prudent and feasible tax planning strategies, in making such assessment. For the three and six months ended June 30, 2024, the valuation allowance was $780,858 and $678,364, respectively.

 

The Company records uncertain tax positions in accordance with ASC Topic 740 on the basis of a two-step process in which (i) the Company determines whether it is more likely than not a tax position will be sustained on the basis of the technical merits of such position and (ii) for those tax positions meeting the more-likely-than-not recognition threshold, the Company would recognize the largest amount of tax benefit that is more than 50.0% likely to be realized upon ultimate settlement with the related tax authority. The Company has determined it had no uncertain tax positions as of June 30, 2024 and 2023. The Company classifies interest and penalties recognized on uncertain tax positions as a component of income tax expense.

 

Recent Accounting Pronouncements

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (ASC 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”), which clarifies that a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, ASU No. 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. The Company’s adoption of ASU 2202-03 did not have a material impact on its financial statements and disclosures.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires disclosure of incremental income tax information within the rate reconciliation and expanded disclosures of income taxes paid, among other disclosure requirements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company’s management does not believe the adoption of ASU 2023-09 will have a material impact on its financial statements and disclosures.

 

Management does not believe that any other recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

 

Note 3 — Initial Public Offering

 

On December 20, 2021, the Company consummated its IPO of 10,000,000 Units at a purchase price of $10.00 per Unit. Each Unit that the Company is offering has a price of $10.00 and consists of one share of common stock and three-fourths of one redeemable warrant. Each whole warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment (see Note 7). On December 20, 2021, the underwriters exercised their full over-allotment option and purchased the additional Units available to them. The aggregate Units sold in the IPO and subsequent over-allotment were 11,500,000 and generated gross proceeds of $115,000,000. 

 

12

 

Following the closing of the IPO on December 20, 2021, $116,725,000 from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was deposited into the Trust Account. This amount was comprised of $10.15 per Unit for the 11,500,000 Units sold in the IPO. Following the closing of the IPO and the exercise of the underwriters’ full over-allotment option, $116,725,000 ($10.15 per Unit) was placed in the Trust Account and will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. 

 

Note 4 — Private Placement Warrants

 

Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 6,500,000 Private Placement Warrants (7,100,000 Private Placement Warrants when the underwriters’ over-allotment option was fully exercised on December 20, 2021), each exercisable to purchase one share of common stock at $11.50 per share, at a price of $1.00 per Private Placement Warrant. The sale of the Private Placement Warrants in connection with the IPO and subsequent over-allotment option exercise generated gross proceeds of $7,100,000. Additionally, 2,300,000 Private Placement Warrants were issued in relation to the extension payments, at a price of $1.00 per warrant, for an aggregate purchase price of $9,400,000. Each Private Placement Warrant is identical to the Public Warrants, except as described below. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Founder Shares, Private Placement Warrants or placement rights, which will expire worthless if the Company does not consummate the initial business combination by the Termination Date.

 

The Private Placement Warrants are not transferable, assignable or salable (and the shares of common stock issuable upon exercise of the Private Placement Warrants are not transferable, assignable or salable until 30 days after the completion of the initial business combination).

 

If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants are redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the Units sold in the Public Offering. Any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants requires a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants.

 

Note 5 — Related Party Transactions

 

Founder Shares

 

On February 23, 2021, the Company issued the Sponsor an aggregate of 2,875,000 shares of the Company’s common stock, par value $0.001 per share (the “Founder Shares”) for an aggregate purchase price of $25,000. The Sponsor has agreed, subject to certain limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) one year following the date of the consummation of the Company’s initial business combination or (B) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Public Stockholders having the right to exchange their shares of common stock for cash, securities or other property. Notwithstanding the foregoing, all Founder Shares will be released from the lock-up if (1) the last reported sale price of the Company’s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Company’s initial business combination or (2) if after a business combination there is a transaction whereby all of the Company’s stockholders have the right to exchange their shares for cash, securities or other property. The Sponsor did not transfer, assign or sell any of the Founder Shares during the six months ended June 30, 2024 or June 30, 2023.

 

Private Placement Warrants

 

The Sponsor purchased an aggregate of 9,400,000 Private Placement Warrants, which includes the purchase of 6,500,000 Private Placement Warrants simultaneously with the closing of the IPO, 600,000 Private Placement Warrants purchased by the Sponsor to account for the underwriters’ exercise of the over-allotment option, and 2,300,000 Private Placement Warrants issued in relation to the extension payments, at a price of $1.00 per warrant, for an aggregate purchase price of $9,400,000. Each Private Placement Warrant is identical to the Public Warrants, except as described below. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Founder Shares, Private Placement Warrants or placement rights, which will expire worthless if the Company does not consummate the initial business combination by the Termination Date.

 

Administrative Services Agreement

 

The Sponsor, through the earlier of the Company’s consummation of the initial business combination and its liquidation, makes available to the Company certain general and administrative services, including office space, utilities, and administrative services, as the Company may require from time to time. The Company has agreed to pay the Sponsor $10,000 per month for these services. The Company incurred $30,000 and $60,000 in operating cost associated with the administrative service fees for each of the three and six months ended June 30, 2024 and 2023, respectively.

 

13

 

Line of Credit

 

On June 30, 2023, we entered into a line of credit agreement (the “Line of Credit”) with Ault, which was subsequently amended twice, effective as of December 15, 2023 and March 5, 2024, which bears interest at 9.5% per annum. The Line of Credit agreement is for 18 months (unless a credit extension is granted by Ault) and provides for up to an aggregate of $1,200,000 of advances from the Sponsor under a promissory note. As of June 30, 2024, we had an outstanding principal advance balance of $950,681 and accrued interest of $37,871 under the Line of Credit agreement. The outstanding principal balance of the promissory note will become due and payable five business days after written demand for repayment is made by Ault. We can prepay any advances without penalty or premium upon notice. If any payment is not made within ten (10) days after the date such payment is due, we shall pay Ault a late fee equal to the lesser of (i) five percent (5%) of the amount of such unpaid amount or (ii) the maximum amount permitted to be charged under applicable law. As of the date of this report, we have not received a demand for repayment from Ault. 

 

Note 6 — Commitments and Contingencies

 

Registration and Stockholder Rights

 

The holders of the Founder Shares, Public Warrants and Private Placement Warrants that may be issued upon conversion of Working Capital Loans (and any shares of common stock issuable upon the exercise of the Private Placement Warrants, including those issued upon conversion of the working capital loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement signed on the effective date of the IPO requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to shares of common stock). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of the initial business combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that no sales of these securities will be effected until after the expiration of the applicable lock-up period, as described herein. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

Underwriting Agreement

 

The underwriters had a 45-day option from the date of the IPO to purchase up to an additional 1,500,000 Units to cover over-allotments, if any. On December 20, 2021, the underwriters fully exercised the over-allotment option. 

 

The underwriters were paid at the closing of the IPO an underwriting commission of $0.25 per Unit sold in the IPO or $2,513,333. Following the exercise of the underwriters’ over-allotment option on December 20, 2021, the underwriters earned an additional $375,000 for an aggregate of $2,888,333 in underwriting commissions related to the IPO and over-allotment.

 

In addition, $3,000,000 is payable to the underwriters for deferred underwriting commissions related to the Units sold in the IPO. Following the exercise of the underwriters’ over-allotment option on December 20, 2021, the underwriters earned an additional $450,000 for an aggregate of $3,450,000 in deferred underwriting commissions related to the IPO and over-allotment. The deferred underwriting commission will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a business combination, subject to the terms of the underwriting agreement. 

 

Excise Tax

 

In connection with the votes to approve the Charter Amendment, 11,311,125 shares of common stock of the Company were tendered for redemption at a per-share price of $10.61 for an aggregate redemption amount of approximately $120,063,828. As such, the Company has recorded a 1% excise tax liability in the amount of $1,200,638 on the balance sheet as of December 31, 2023. This excise tax liability can be offset by future share issuances within the same fiscal year which will be evaluated and adjusted in the period in which the issuances occur.

 

In connection with the Second Special Meeting, the Company redeemed 121,695 shares from its public stockholders at a redemption price of approximately $11.61 per share. There are 2,942,180 non-redeemed shares remaining as of the date of this quarterly report, of which 2,875,000 are held by the Sponsor. During the three months ended March 31, 2024, we recognized an additional $14,268 in excise tax payable related to share redemptions of 121,695 shares. As of June 30, 2024, the Company has recognized $1,214,906 in excise tax payable.

 

14

 

Note 7 — Stockholders’ Equity

 

Preferred Stock

 

The Company is authorized to issue 1,000,000 preferred shares with a par value of $0.001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2024 and December 31, 2023, there were no preferred shares issued or outstanding. 

 

Common Stock

 

The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.001 per share. As of June 30, 2024 and December 31, 2023, there were 2,875,000 shares of common stock outstanding, excluding 67,180 and 188,875 shares of common stock subject to possible redemption issued, respectively.

 

Founder Shares

 

On February 23, 2021, the Sponsor purchased 2,875,000 Founder Shares for an aggregate price of $25,000.

 

The Sponsor agreed, subject to certain limited exceptions, not to transfer, assign or sell their Founder Shares, for a period ending on the date that is the earlier of (A) one year following the date of the consummation of the Company’s initial business combination or (B) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Public Stockholders having the right to exchange their shares of common stock for cash, securities or other property. Notwithstanding the foregoing, all Founder Shares will be released from the lock-up if (1) the last reported sale price of the Company’s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Company’s initial business combination or (2) if after a business combination there is a transaction whereby all of the Company’s stockholders have the right to exchange their shares for cash, securities or other property.

 

Public Warrants and Private Placement Warrants

 

Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants were issued upon separation of the Units and only whole Public Warrants trade. The Public Warrants will become exercisable on the later of (a) one year after the date that the registration statement for the offering is declared effective by the SEC and (b) the consummation of a business combination; provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available.

 

The Public Warrants have an exercise price of $11.50 per share, subject to adjustment as described herein. In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the consummation of the Company’s initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial business combination on the date of the consummation of the Company’s initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial business combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price.

 

If a registration statement covering the issuance of the shares of common stock issuable upon exercise of the warrants is not effective by the 60th business day following the consummation of the Company’s initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.

 

Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants):

 

•

in whole and not in part;

 

•

at a price of $0.01 per warrant;

 

15

 

•

upon not less than 30 days’ prior written notice of redemption given after the warrants become exercisable (the “30-day redemption period”) to each warrant holder; and

 

•

if, and only if, the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending three days before the Company sends the notice of redemption to the warrant holders.

 

The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the shares of common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of common stock is available throughout the 30-day redemption period, except if the warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act. If and when the warrants become redeemable by the Company, the Company may not exercise its redemption right if the issuance of shares of common stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or the Company is unable to effect such registration or qualification. The Company will use its best efforts to register or qualify such shares of common stock under the blue sky laws of the state of residence in those states in which the warrants were offered by the Company in the Public Offering.

 

If the Company calls the warrants for redemption as described above, the Company’s management will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In determining whether to require all holders to exercise their warrants on a “cashless basis,” the Company’s management will consider, among other factors, its cash position, the number of outstanding warrants and the dilutive effect on the Company’s stockholders of issuing the maximum number of shares of common stock issuable upon the exercise of the Company’s warrants. In such an event, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” for this purpose shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.

 

The Sponsor purchased an aggregate of 9,400,000 Private Placement Warrants, which includes the purchase of 6,500,000 Private Placement Warrants simultaneously with the closing of the IPO, 600,000 Private Placement Warrants purchased by the Sponsor to account for the underwriters’ exercise of the over-allotment option, and 2,300,000 Private Placement Warrants issued in relation to the extension payments, at a price of $1.00 per warrant, for an aggregate purchase price of $9,400,000. Each Private Placement Warrant is identical to the Public Warrants, except as described below. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Founder Shares, Private Placement Warrants or placement rights, which will expire worthless if the Company does not consummate the initial business combination by the Termination Date.

 

All warrants relating to the IPO are financial instruments that are classified as equity in accordance with ASC Topic 815.

 

NYSE Regulation Notice of Noncompliance

 

On July 19, 2023, the Company received a letter (the “Letter”) from the staff of NYSE of the New York Stock Exchange (“NYSE”) indicating that the Company is not currently in compliance with (i) Section 1003(b)(i)(A) of the NYSE American LLC (“NYSE American”) Company Guide (the “Company Guide”), which requires the Company to maintain a minimum of 200,000 shares publicly held on a continuous basis (the “Minimum Public Float”), and (ii) Section 1003(b)(i)(B) of the Company Guide, which requires the Company to maintain a minimum of 300 public stockholders on a continuous basis (the “Minimum Public Holders”).

 

On August 18, 2023, the Company submitted a plan of compliance (the “Plan”) to the NYSE American addressing how it intends to regain compliance with these requirements by December 15, 2024. On September 27, 2023, the Company received notice from the NYSE American that it had accepted the Plan and granted a Plan period until December 15, 2024, in order to regain compliance. The Company’s progress toward regaining compliance is subject to periodic review by the NYSE American, including quarterly monitoring for compliance with the initiatives outlined in the Plan. However, there can be no assurance that the Company will be able to satisfy the NYSE American’s continued listing requirements, regain compliance with the Minimum Public Float and Minimum Public Holders requirements, or maintain compliance with the other listing requirements.

 

16

 

Note 8 — Fair Value Measurements

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

●

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

 

●

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

●

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

		June 30,				Quoted Prices In Active Markets				Significant Other Observable Inputs				Significant Other Unobservable Inputs
		2024				(Level 1)				(Level 2)				(Level 3)
Description
Assets:
U.S. Money Market Funds held in the Trust Account		$	794,112			$	794,112			$	-			$	-
Total		$	794,112			$	794,112			$	-			$	-

 

		December 31,				Quoted Prices In Active Markets				Significant Other Observable Inputs				Significant Other Unobservable Inputs
		2023				(Level 1)				(Level 2)				(Level 3)
Description
Assets:
U.S. Money Market Funds held in the Trust Account		$	2,200,308			$	2,200,308			$	-			$	-
Total		$	2,200,308			$	2,200,308			$	-			$	-

 

There were no transfers between Levels 1, 2 or 3 during the six months ended June 30, 2024 and the fiscal year ended December 31, 2023.

 

Note 9 — Subsequent Events

  

The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date that the financial statements were issued. Based on this, other than those discussed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements. 

 

On August 15, 2024, we entered into a third amendment to the Line of Credit with Ault, which bears interest at 9.5% per annum. The Line of Credit provides for up to an aggregate of $ 1,500,000 of advances from Ault.

 

17

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

References to the “Company,” “ADRT” “our,” “us” or “we” refer to Ault Disruptive Technologies Corporation. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings.

 

Overview

 

We are a blank check company incorporated in February 2021 (“Inception”) as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to as our “initial business combination” throughout this Quarterly Report. While our efforts to identify a target business may span many industries and regions worldwide, we are likely to focus our search for prospects within the technology sector, which has experienced significant disruption from new and emerging products and services. We have entered into an Agreement and Plan of Merger as discussed below. We intend to effectuate our initial business combination using cash from the proceeds of the IPO and the sale of the Placement Warrants, the proceeds of the sale of our shares in connection with our initial business combination (including pursuant to backstop agreements we may enter into), shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, or a combination of the foregoing.

 

We believe that Gresham Worldwide, Inc., which is discussed below under the heading “Merger Agreement,” constitutes a business with disruptive technologies that our management team believes can achieve mainstream adoption and create opportunities for long-term appreciation in value.

 

The registration statement for the Company’s IPO was declared effective on December 15, 2021. On December 20, 2021, the Company’s commenced the IPO of 10,000,000 units at $10.00 per unit (the “Unit”). Each Unit consisted of one share of common stock, par value $0.001 per share, and three-fourths of one redeemable warrant. Each whole warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share. On December 20, 2021, the underwriters exercised their full over-allotment option and purchased the additional Units available to them. The aggregate Units sold in the IPO and subsequent over-allotment were 11,500,000 and generated gross proceeds of $115,000,000.

 

The Company’s Sponsor is Ault Disruptive Technologies Company, LLC.

 

Simultaneously with the consummation of the IPO, the Company consummated the private placement of 7,100,000 warrants (the “Placement Warrants”) to the Sponsor, at a price of $1.00 per Placement Warrant. The sale of the Placement Warrants in connection with the IPO and subsequent over-allotment option exercise generated gross proceeds of $7,100,000.

 

To date, our efforts have been limited to organizational activities, including our IPO, as well as searching for a suitable acquisition target. We are not prohibited from pursuing an initial business combination with a business that is owned by the Sponsor or any of the related companies or making the acquisition through a joint venture or other form of shared ownership with any of them.

 

Our executive offices are located at 11411 Southern Highlands Parkway, Suite 240, Las Vegas, Nevada 89141, and our telephone number is [phone].

 

Merger Agreement

 

On June 23, 2024, ADRT entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) by and among ADRT, ADRT Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of ADRT (“Merger Sub”), and Gresham Worldwide, Inc., a California corporation (“Gresham”). The transactions contemplated by the Merger Agreement are referred to herein as the “Business Combination.”

 

18

 

Pursuant to the Merger Agreement and subject to the terms and conditions set forth therein, the Merger Sub was intended to merge with and into Gresham (the “Merger”), with Gresham being the surviving corporation and thereby becoming a wholly owned subsidiary of ADRT. Upon the Closing of the Business Combination (the “Effective Time”), it was expected that ADRT would be renamed Gresham Worldwide, Inc., and thereafter remain listed on the NYSE American under a new ticker symbol, “GWWI.”

 

However, on August 14, 2024, Gresham filed a petition for reorganization under Chapter XI of the bankruptcy laws. Consequently, ADRT was required to terminate the Merger Agreement, which it did on August 15, 2024. It is uncertain whether we will enter into a new agreement and plan of merger with a third party.

 

Going Concern

 

In connection with our assessment of going concern considerations in accordance with the Financial Accounting Standards Board’s (“FASB’s”) Accounting Standards Update (“ASU”) 2014-15, Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern, we have until December 20, 2024 to consummate a business combination. It is uncertain that we will be able to consummate a business combination by this time. If a business combination is not consummated by this date and an extension of the period of time we have to complete a business combination has not been approved by our stockholders, there will be a mandatory liquidation and subsequent dissolution of our company. We have determined that mandatory liquidation and potential subsequent dissolution, coupled with our working capital deficit, raise substantial doubt about our ability to continue as a going concern for one year from the date these financial statements are issued. No adjustments have been made to the carrying amounts of assets or liabilities should we be required to liquidate after December 20, 2024. We intend to continue to complete a business combination before the mandatory liquidation date.

 

The unaudited financial statements presented in this Quarterly Report on Form 10-Q have been prepared on a going concern basis and do not include any adjustments that might arise as a result of uncertainties about our ability to continue as a going concern.

 

Results of Operations

 

Our entire activity from Inception through June 30, 2024 relates to our formation, the IPO and since the closing of the IPO, a search for a business combination candidate. We will not be generating any operating revenues until the closing and completion of our initial business combination, at the earliest.

 

For the three months ended June 30, 2024 and June 30, 2023, we had a net loss of $246,152 and net income of $525,344, respectively. Net loss for the three months ended June 30, 2024 consisted of $10,219 in income from investments held in the Trust Account and $4,481 of an income tax benefit, offset by $239,040 in operating costs and $21,812 of interest expense. Net income for the three months ended June 30, 2023 consisted of $1,279,341 in income from investments held in the Trust Account, offset by $455,964 in operating costs and $298,033 of income tax expense.

 

For the six months ended June 30, 2024 and June 30, 2023, we had a net loss of $555,963 and net income of $1,081,016, respectively. Net loss for the six months ended June 30, 2024 consisted of $31,182 in income from investments held in the Trust Account and $4,723 of an income tax benefit, offset by $553,998 in operating costs and $37,870 of interest expense. Net income for the six months ended June 30, 2023 consisted of $2,532,744 in income from investments held in the Trust Account, offset by $814,852 in operating costs and $636,876 of income tax expense.

 

Liquidity and Capital Resources

 

Prior to the completion of the IPO, our liquidity needs had been satisfied through a capital contribution from the Sponsor of $25,000, to cover certain offering costs, for the founder shares, and the loan under an unsecured promissory note in the principal amount of $1,500,000 from our sponsor. Our liquidity needs have been satisfied through the proceeds from the consummation of the Private Placement not held in the Trust Account, together with additional loans from the Sponsor.

 

19

 

On December 13, 2022, we received notice from our Sponsor of the Sponsor’s intention to deposit $1,150,000 into the Trust Account (the “First Deposit”). The First Deposit was required to extend the period of time we have to consummate our initial business combination by three months from the initial deadline of December 20, 2022 (12 months from the date of the IPO) until March 20, 2023. On March 15, 2023, we received notice from our Sponsor of the Sponsor’s intention to deposit another $1,150,000 into the Trust Account (the “Second Deposit” and together with the First Deposit, the “Deposits”). The Second Deposit was required to extend the period of time we have to consummate our initial business combination by three months from the first extension deadline of March 20, 2023 until June 20, 2023. The two automatic extensions that occurred on December 20, 2022 and March 20, 2023 were paid in full and the Sponsor received 2,300,000 Private Placement Warrants.

 

On June 15, 2023, we held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, our stockholders approved two proposals amending our Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to (i) extend the date by which we must complete an initial business combination from June 20, 2023 to September 20, 2023 (“Charter Extension Date”) and to allow us, without another stockholder vote, to elect to extend the Charter Extension Date to consummate an initial business combination on a monthly basis up to five times by an additional one month each time after September 20, 2023, upon the request by the Sponsor, and approval by the Board, until February 20, 2024 or a total of up to eight months, unless the closing of an initial business combination shall have occurred prior thereto and (ii) delete (a) the limitation that we shall not consummate an initial business combination if it would cause our net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act (or any successor rule)) to be less than $5,000,0001 following such redemptions and (b) the limitation that we shall not redeem public shares that would cause our net tangible assets to be less than $5,000,001 following such redemptions.

 

In connection with the votes to approve the Charter Amendment, 11,311,125 shares of our common stock were tendered for redemption at a per-share price of $10.61. This resulted in a redemption from the Trust Account in the amount of approximately $120,064,000.

 

On June 30, 2023, we entered into a line of credit agreement (the “Line of Credit”) with Ault, which was subsequently amended three times, effective as of December 15, 2023, March 5, 2024 and August 15, 2024, which bears interest at 9.5% per annum. The term of the Line of Credit agreement is for 18 months from June 30, 2023, its date of execution (unless a credit extension is granted by Ault) and provides for up to an aggregate of $ 1,500,000 of advances from the Sponsor under a promissory note. As of June 30, 2024, we had an outstanding principal advance balance of $950,681 and accrued interest of $37,871 under the Line of Credit agreement. The outstanding principal balance of the promissory note will become due and payable five business days after written demand for repayment is made by Ault. We can prepay any advances without penalty or premium upon notice. If any payment is not made within ten (10) days after the date such payment is due, we shall pay Ault a late fee equal to the lesser of (i) five percent (5%) of the amount of such unpaid amount or (ii) the maximum amount permitted to be charged under applicable law. As of the date of this report, we have not received a demand for repayment from Ault.

 

At June 30, 2024 and December 31, 2023, funds held in the Trust Account included $794,112 and $2,200,308, respectively, of investments held in a money market fund characterized as Level 1 investments within the fair value hierarchy under ASC Topic 820, Fair Value Measurements and Disclosures. The funds were invested in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. All of our investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. During the six months ended June 30, 2024, we withdrew $1,426,814 in relation to common stock redemptions. 

  

We intend to use substantially all of the funds held in the Trust Account, including any amounts representing income earned on the Trust Account (less deferred underwriting commissions and taxes payable), to complete our initial business combination. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our business combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies. For the six months ended June 30, 2024, cash used in operating activities was $573,221 primarily related to operating costs, payables, expenses, and income taxes paid. For the six months ended June 30, 2023, cash used in operating activities was $574,704, primarily related to operating costs, income from investments held in the Trust Account, payables, expenses, and income taxes paid.

 

In addition, in order to finance transaction costs in connection with a business combination, our Sponsor or an affiliate of the Sponsor, or certain of our officers and directors may, but are not obligated to, provide us with funds as may be required (“Working Capital Loans”). As of June 30, 2024, there were no Working Capital Loans.

 

We anticipate that we will need to borrow additional funds, through Working Capital Loans, to allow us to operate until we consummate a business combination or are forced to wind up operations if a business combination is not consummated before any applicable extensions expire. We intend to use the funds held outside the Trust Account, and any Working Capital Loans from our Sponsor, an affiliate of our Sponsor or certain of our directors and officers, primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate and complete a business combination. If we are unable to raise additional capital, we may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. We cannot provide any assurance that new financing will be available to us on commercially acceptable terms, if at all.

 

20

 

We may need to raise additional capital through loans or additional investments from our Sponsor, stockholders, officers, directors, or third parties. Our officers, directors and our Sponsor may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet our working capital needs. Accordingly, we may not be able to obtain additional financing. If we are unable to raise additional capital, we may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. We cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. We will provide our public stockholders with the opportunity to redeem all or a portion of their shares of our common stock upon the consummation of our initial business combination, subject to the limitations described herein.

 

Contractual Obligations

 

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than an agreement to pay an affiliate of the Sponsor a monthly fee of $10,000 for office space, administrative and support services to us. We began incurring these fees on January 1, 2022 and will continue to incur these fees monthly until the earlier of the completion of the business combination or our liquidation. 

 

The underwriters of the IPO are entitled to a deferred fee of $3,450,000 in the aggregate. The deferred fee will be waived by the underwriters in the event that we do not complete a business combination, subject to the terms of the underwriting agreement.

 

The unsecured promissory note in the principal amount of $1,500,000 from our Sponsor bears no interest and is repayable in full at the date on which we consummate an initial business combination as contemplated by our amended and restated certificate of incorporation. Such promissory note bears no interest and is repayable in full at the date on which we consummate an initial business combination as contemplated by our amended and restated certificate of incorporation.

 

JOBS Act

 

We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. 

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non- emerging growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. 

 

Critical Accounting Policies

 

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:

 

Common Stock Subject to Possible Redemption

 

We account for our shares of common stock subject to possible redemption in accordance with the guidance in accounting standards codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity (“ASC Topic 480”). Shares of common stock subject to mandatory redemption are classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. Our common stock features certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, the common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ deficit section of our balance sheet.

 

21

 

Net Loss per Share of Common Stock

 

We comply with accounting and disclosure requirements of ASC Topic 260, Earnings Per Share. Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. Remeasurement associated with the redeemable shares of common stock is excluded from net loss per share as the redemption value approximates fair value. At June 30, 2024 and 2023, we did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into shares of common stock and then share in our earnings. As a result, diluted loss per share is the same as basic loss per share for the period presented.

 

Derivatives

 

We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. We evaluate all of our financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 480 and ASC Topic 815, Derivatives and Hedging (“ASC Topic 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period.

 

We accounted for the 8,625,000 Public Warrants and the 9,400,000 Private Placement Warrants issued in connection with the IPO and Private Placement in accordance with the guidance contained in ASC Topic 480 and ASC Topic 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC Topic 480, meet the definition of a liability pursuant to ASC Topic 480, or whether the instruments meet all of the requirements for equity classification under ASC Topic 815, including whether the instruments are indexed to our common stock and whether the holders could potentially require “net cash settlement” in a circumstance outside of our control in which the holders of the shares underlying the contract also would receive cash, among other conditions for equity classification.

 

The Public Warrants and Private Placement Warrants were deemed to meet equity classification.

 

Critical Accounting Estimates

 

The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have not identified any critical accounting estimates.

 

Recent Accounting Standards

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (ASC 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, (“ASU 2022-03”), which clarifies that a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, ASU No. 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Our adoption of ASU 2022-03 did not have a material impact on our financial statements and disclosures.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, (“ASU 2023-09”), which requires disclosure of incremental income tax information within the rate reconciliation and expanded disclosures of income taxes paid, among other disclosure requirements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. Our management does not believe the adoption of ASU 2023-09 will have a material impact on our financial statements and disclosures.

 

Management does not believe that any other recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on our financial statements.

 

As an emerging growth company, we are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We can delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, the financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

 

22

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

Not applicable for a smaller reporting company.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended June 30, 2024, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our chief executive officer and chief financial officer have concluded that during the period covered by this report, our disclosure controls and procedures were effective.

 

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. 

 

Changes in Internal Control over Financial Reporting

 

There were no changes to our internal control over financial reporting that occurred during our fiscal quarter ended June 30, 2024, that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

 

23

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

There is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such.

 

Item 1A. Risk Factors.

 

As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 11, 2024.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Use of Proceeds

 

On December 20, 2021, we sold 11,500,000 units, including 1,500,000 units pursuant to the exercise of the underwriters’ over-allotment option in full, at a purchase price of $10.00 per unit in our IPO. Simultaneously with the closing of the IPO, we consummated the private placement of 7,100,000 private warrants for an aggregate purchase price of $7,100,000 (the “Private Placement”). Following the closing of the IPO and the Private Placement on December 20, 2021, $116,725,000 from the net proceeds of the sale of the units in the IPO and the sale of the private placement units was deposited into our trust account (the “Trust Account”), and $1,849,679 of cash was held outside of the Trust Account and is available for our working capital purposes. Transaction costs amounted to $7,087,891 in transaction costs, including $6,338,333 of underwriting fees ($3,450,000 consisted of deferred underwriting fees) and $749,558 of other costs.

 

We received an aggregate of $2,331,995 of deposits into the Trust Account from our Sponsor for the payment of fees to extend the period of time we have to consummate our initial business combination until June 20, 2023. In June 2023, in connection with the vote to approve an amendment to the Certificate of Incorporation to extend the date by which we must have consummated our initial business combination until February 20, 2024, 11,311,125 shares of common stock were tendered for redemption at a per-share price of $10.61 for an aggregate redemption amount of approximately $120,063,828. In February 2024, in connection with the vote to approve another amendment to the Certificate of Incorporation to extend the date we have to consummate our initial business combination until December 20, 2024, 121,695 shares of common stock were tendered for redemption at a per-share price of $11.61 for an aggregate redemption amount of approximately $1,412,879.

 

The net proceeds deposited into the Trust Account are invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations.

 

In connection with such deposit payments for the extensions mentioned above, our Sponsor, now currently holds 9,400,000 private placement warrants (consisting of the private placement of 6,500,000 warrants upon consummation of the IPO, the underwriters’ over-allotment option, of 600,000 private placement warrants, that was fully exercised on December 20, 2021 and 2,300,000 Private Placement Warrants related to the extension of the time we have to consummate the initial business combination in exchange for $2,300,000).

 

There has been no other material change in the planned use of the proceeds from the IPO, the Private Placement, and extension fees.

 

Item 3.

Defaults Upon Senior Securities.

 

None.

 

Item 4.

Mine Safety Disclosures.

 

Not Applicable.

 

Item 5.

Other Information.

 

Not Applicable.

 

24

 

Item 6.

Exhibits.

 

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

 

Exhibit		Description
2.1+#		Agreement and Plan of Merger, dated as of June 23, 2024, by and among Ault Disruptive Technologies Corporation, ADRT Merger Sub, Inc., and Gresham Worldwide, Inc. Incorporated herein by reference to the Current Report on Form 8-K filed on June 27, 2024, as Exhibit 2.1 thereto.
3.1		Certification of Incorporation. Incorporated herein by reference to the Registration Statement on Form S-1 filed on November 5, 2021, as Exhibit 3.1 thereto.
3.2		Amended and Restated Certificate of Incorporation. Incorporated herein by reference to the Current Report on Form 8-K filed on December 20, 2021, as Exhibit 3.1 thereto.
3.3		By-Laws. Incorporated herein by reference to the Registration Statement on Form S-1 filed on November 5, 2021, as Exhibit 3.3 thereto.
3.4		Amendment to Amended and Restated Certificate of Incorporation. Incorporated herein by reference to the Current Report on Form 8-K filed on June 16, 2023, as Exhibit 3.1 thereto.
3.5		Certificate of Amendment to the Amended and Restated Certificate of Incorporation. Incorporated herein by reference to the Current Report on Form 8-K filed on February 16, 2024, as Exhibit 3.1, thereto.
31.1*		Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
31.2*		Certification of the Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).
32.1**		Certification of the Chief Executive Officer and Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
101.INS*		XBRL Instance Document.  The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*		XBRL Taxonomy Extension Schema Document
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document
104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

*

Filed herewith.

**

Furnished herewith.

+

Certain of the schedules (and similar attachments) to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K under the Securities Act of 1933, as amended, because they do not contain information material to an investment or voting decision and that information is not otherwise disclosed in the exhibit or the disclosure document. The registrant hereby agrees to furnish a copy of all omitted schedules (or similar attachments) to the SEC upon its request.

#

Portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K under the Securities Act of 1933, as amended, because they are both (i) not material and (ii) the type that the registrant treats as private or confidential. A copy of the omitted portions will be furnished to the SEC upon its request.

 

25

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	Ault Disruptive Technologies Corporation
Dated: August 16, 2024	/s/ William B. Horne
	William B. Horne
	Chief Executive Officer
	(Principal Executive Officer)
Dated: August 16, 2024	/s/ Kenneth S. Cragun
	Kenneth S. Cragun
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

 

 

26

 

 

 

 

EXHIBIT 31.1

CERTIFICATION

 

I, William B. Horne, certify that:

 

1.  I have reviewed this quarterly report on Form 10-Q of Ault Disruptive Technologies Corporation;

 

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.  The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated:  August 16, 2024

 

/s/ William B. Horne
Name: William B. Horne
Title: Chief Executive Officer
(Principal Executive Officer)

 

 

 

 

 

 

 

EXHIBIT 31.2

CERTIFICATION

 

I, Kenneth S. Cragun, certify that:

 

1.  I have reviewed this quarterly report on Form 10-Q of Ault Disruptive Technologies Corporation;

 

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.  The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated:  August 16, 2024

 

/s/ Kenneth S. Cragun
Name: Kenneth S. Cragun
Title: Chief Financial Officer
(Principal Accounting Officer)

 

 

 

 

 

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of Ault Disruptive Technologies Corporation (the “Company”) on Form 10-Q for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. 

 

Date: August 16, 2024
	By: /s/ William B. Horne
	Name: William B. Horne
	Title: Chief Executive Officer
	(Principal Executive Officer)

 

Date: August 16, 2024
	By: /s/ Kenneth S. Cragun
	Name: Kenneth S. Cragun
	Title: Chief Financial Officer
	(Principal Accounting Officer)

 

 

 

 

  

Cover - shares	6 Months Ended
	Jun. 30, 2024	Aug. 14, 2024
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-41171
Entity Registrant Name	AULT DISRUPTIVE TECHNOLOGIES CORPORATION
Entity Central Index Key	0001864032
Entity Tax Identification Number	86-2279256
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	11411 Southern Highlands Pkwy
Entity Address, Address Line Two	Suite 240
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89141
City Area Code	(949)
Local Phone Number	444-5464
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		2,942,180
Units, each consisting of one share of common stock, par value $0.001 per share and three-fourths of one redeemable warrant to purchase one share of common stock
Title of 12(b) Security	Units, each consisting of one share of common stock, par value
Trading Symbol	ADRU
Security Exchange Name	NYSEAMER
Common stock, $0.001 par value
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	ADRT
Security Exchange Name	NYSEAMER

BALANCE SHEETS (Unaudited) - USD ($)		Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash		$ 866	$ 163,235
Prepaid expenses		42,500	10,873
Total current assets		43,366	174,108
Cash and marketable securities held in the trust account (the “Trust Account”)		794,122	2,200,308
Deferred tax asset, noncurrent		9,446
Total Assets		846,934	2,374,416
Current liabilities:
Accounts payable		423,045	256,937
Accrued expenses		66,834	48,985
Accrued excise tax		1,214,906	1,200,638
Income tax payable		3,393	132,353
Related party note payable		950,681	550,383
Total current liabilities		2,658,859	2,189,296
Deferred underwriting commissions		3,450,000	3,450,000
Total liabilities		6,108,859	5,639,296
Commitments
Common stock subject to possible redemption, 67,180 shares and 188,875 shares at redemption value as of June 30, 2024 and December 31, 2023, respectively	[1]	794,845	2,201,557
Stockholders’ Deficit:
Preferred stock, $0.001 par value; 1,000,000 shares authorized; none issued and outstanding
Common stock, $0.001 par value; 100,000,000 shares authorized; 2,875,000 shares issued and outstanding (excluding 67,180 and 188,875 shares subject to possible redemption) as of June 30, 2024 and December 31, 2023, respectively		2,875	2,875
Accumulated deficit		(6,059,645)	(5,469,312)
Total stockholders’ deficit		(6,056,770)	(5,466,437)
Total Liabilities, Commitments and Stockholders’ Deficit		$ 846,934	$ 2,374,416
[1] Redemption value is net of amounts eligible to be withdrawn from the Trust Account to pay franchise and income taxes.

BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, shares authorized redemption	67,180	188,875
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	2,875,000	2,875,000
Common stock, shares outstanding	2,875,000	2,875,000
Common stock subject to possible redemption issued	67,180	188,875

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating costs	$ 239,040	$ 455,964	$ 553,998	$ 814,852
Loss from operations	(239,040)	(455,964)	(553,998)	(814,852)
Other income:
Income from investments held in the Trust Account	10,219	1,279,341	31,182	2,532,744
Interest expense, net	(21,812)		(37,870)
Total other (loss) income, net	(11,593)	1,279,341	(6,688)	2,532,744
Net (loss) income before income taxes	(250,633)	823,377	(560,686)	1,717,892
Provision for income taxes	(4,481)	298,033	(4,723)	636,876
Net (loss) income	$ (246,152)	$ 525,344	$ (555,963)	$ 1,081,016
Common Stock Subject to Mandatory Redemption [Member]
Other income:
Weighted average shares outstanding, basic	67,180	10,505,615	101,281	11,000,061
Weighted average shares outstanding, diluted	67,180	10,505,615	101,281	11,000,061
Basic net income (loss) per share attributable to common stockholders	$ (0.08)	$ 0.04	$ (0.19)	$ 0.08
Diluted net income (loss) per share attributable to common stockholders	$ (0.08)	$ 0.04	$ (0.19)	$ 0.08
Non Redeemable Common Stock [Member]
Other income:
Weighted average shares outstanding, basic	2,875,000	2,875,000	2,875,000	2,875,000
Weighted average shares outstanding, diluted	2,875,000	2,875,000	2,875,000	2,875,000
Basic net income (loss) per share attributable to common stockholders	$ (0.08)	$ 0.04	$ (0.19)	$ 0.08
Diluted net income (loss) per share attributable to common stockholders	$ (0.08)	$ 0.04	$ (0.19)	$ 0.08

STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)		Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2022		$ 2,875		$ (2,969,983)	$ (2,967,108)
Beginning balance, shares at Dec. 31, 2022		2,875,000
Remeasurement adjustment on redeemable common stock, net	[1]			(872,023)	(872,023)
Net income				555,672	555,672
Ending balance, value at Mar. 31, 2023		$ 2,875		(3,286,334)	(3,283,459)
Ending balance, shares at Mar. 31, 2023		2,875,000
Remeasurement adjustment on redeemable common stock, net	[1]			(1,010,609)	(1,010,609)
Excise tax imposed on common stock redemptions				(1,200,638)	(1,200,638)
Net income				525,344	525,344
Ending balance, value at Jun. 30, 2023		$ 2,875		(4,972,236)	(4,969,361)
Ending balance, shares at Jun. 30, 2023		2,875,000
Beginning balance, value at Dec. 31, 2023		$ 2,875		(5,469,312)	(5,466,437)
Beginning balance, shares at Dec. 31, 2023		2,875,000
Remeasurement adjustment on redeemable common stock, net	[2]			(15,145)	(15,145)
Excise tax imposed on common stock redemptions				(14,268)	(14,268)
Net income				(309,811)	(309,811)
Ending balance, value at Mar. 31, 2024		$ 2,875		(5,808,536)	(5,805,661)
Ending balance, shares at Mar. 31, 2024		2,875,000
Remeasurement adjustment on redeemable common stock, net	[2]			(4,957)	(4,957)
Net income				(246,152)	(246,152)
Ending balance, value at Jun. 30, 2024		$ 2,875		$ (6,059,645)	$ (6,056,770)
Ending balance, shares at Jun. 30, 2024		2,875,000
[1] Remeasurement adjustment is net of amounts eligible to be withdrawn from the Trust Account to pay franchise and income taxes for the period. [2] Remeasurement adjustment is net of amounts eligible to be withdrawn from the Trust Account to pay franchise and income taxes for the period.

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net (loss) income	$ (555,963)	$ 1,081,016
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Income from investments held in the Trust Account	(31,182)	(2,532,744)
Changes in current assets and current liabilities:
Prepaid expenses	(31,627)	195,721
Accounts payable	166,108	439,808
Accrued expenses	17,849	(156,381)
Income tax payable	(138,406)	397,876
Net cash used in operating activities	(573,221)	(574,704)
Cash flows from investing activities:
Cash withdrawn from the Trust Account for tax obligations	10,554	851,339
Extension payments deposited into the Trust Account		(2,300,000)
Extension fee interest payments deposited into the Trust Account		(31,995)
Cash withdrawn from the Trust Account in connection with redemptions	1,426,814	120,063,828
Net cash provided by investing activities	1,437,368	118,583,172
Cash flows from financing activities:
Proceeds from related party notes payable	400,298
Proceeds from extension fees		2,300,000
Proceeds from extension fee interest earned		31,995
Payment from the Trust Account in connection with redemptions	(1,426,814)	(120,063,828)
Net cash used in financing activities	(1,026,516)	(117,731,833)
Net change in cash	(162,369)	276,635
Cash, beginning of the period	163,235	206,527
Cash, end of the period	866	483,162
Supplemental non-cash investing and financing activities:
Excise tax liability arising from redemption of common stock	14,268	1,200,638
Remeasurement of common stock subject to possible redemption	$ 20,102	$ 1,882,632

Organization and Business Operations	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	Note 1 — Organization and Business Operations   Organization   Ault Disruptive Technologies Corporation (the “Company,” “ADRT,” “we,” or “our”) is a blank check company organized on February 22, 2021, under the laws of the State of Delaware. The Company was formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities (“initial business combination”).   As of June 30, 2024, the Company had not commenced any operations. All activity for the period from February 22, 2021 through June 30, 2024, related to the Company’s formation, the initial public offering (“IPO” or “Public Offering”) described below and the search for an initial business combination. The Company will not generate any operating revenues until after the completion of its initial business combination, at the earliest. The Company will generate nonoperating income in the form of interest income on cash and cash equivalents from the proceeds derived from the IPO and the sale of the Private Placement Warrants (as defined below). The Company has selected December 31 as its fiscal year end.   The Company’s sponsor is Ault Disruptive Technologies Company, LLC, a Delaware limited liability company (the “Sponsor”), which is a wholly owned subsidiary of Ault Alliance, Inc., a Delaware corporation (NYSE American: AULT) (“Ault”).   Financing    The registration statement for the Company’s IPO was declared effective on December 15, 2021 (the “Effective Date”). On December 20, 2021, the Company consummated its IPO of 10,000,000 units at $10.00 per unit (the “Units”), which is discussed in Note 3. Each Unit consists of one share of common stock, par value $0.001 per share and three-fourths of one redeemable warrant (the “Public Warrants”). Each whole Public Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share. On December 20, 2021, the underwriters exercised their full over-allotment option and purchased the additional Units available to them. The aggregate Units sold in the IPO and subsequent over-allotment were 11,500,000 and generated gross proceeds of $115,000,000.    Simultaneously with the consummation of the IPO, the Company consummated the private placement of 6,500,000 warrants (7,100,000 warrants when the underwriters’ over-allotment option was fully exercised on December 20, 2021) (the “Private Placement Warrants”), at a price of $1.00 per Private Placement Warrant in a private placement. The sale of the Private Placement Warrants in connection with the IPO and subsequent over-allotment option exercise generated gross proceeds of $7,100,000.    Transaction costs related to the IPO amounted to $6,297,333 consisting of $2,513,333 of underwriting commissions, $3,000,000 of deferred underwriting commissions, and $784,000 of other offering costs. The underwriters’ exercise of their full over-allotment option generated an additional $825,000 in transaction costs for aggregate transaction costs of $7,122,333 consisting of $2,888,333 of underwriting commissions, $3,450,000 of deferred underwriting commissions and $784,000 of other offering costs. In addition, $1,849,679 of cash was held outside of the Trust Account (as defined below) and used for working capital purposes.   Initial Business Combination   The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating the initial business combination.   The Company must complete one or more initial business combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the interest earned in the Trust Account) at the time of signing a definitive agreement in connection with the initial business combination. However, the Company will complete the initial business combination only if the post-business combination company in which its public stockholders own shares will own or acquire 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to complete a business combination successfully or on a timely basis.   On December 13, 2022, the Company received notice from the Sponsor of the Sponsor’s intention to deposit $1,150,000 into the Trust Account established in connection with the Company’s initial public offering (the “First Deposit”). The First Deposit was required to extend the period of time the Company will have to consummate its initial business combination by three months from the initial deadline of December 20, 2022 until March 20, 2023. When the Sponsor made the First Deposit, it received 1,150,000 Private Placement Warrants.   On June 1, 2023, the Sponsor made deposit payments totaling $2,331,995, including $31,995 of interest, for previously elected extensions of the period the Company had to consummate its initial business combination by six months from the initial deadline of December 20, 2022, until June 20, 2023, and received 2,300,000 Private Placement Warrants. The Company’s Sponsor currently holds 9,400,000 Private Placement Warrants (consisting of the private placement of 6,500,000 warrants upon consummation of the IPO, the underwriters’ over-allotment option of 600,000 that was fully exercised on December 20, 2021, and the required outstanding deposit payment of $2,300,000 to purchase 2,300,000 Private Placement Warrants, related to the Company’s extension of the time it had to consummate the initial business combination).   On June 15, 2023, the Company held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders approved two proposals amending the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to (i) extend the date by which the Company must complete an initial business combination from June 20, 2023 to September 20, 2023 (“Charter Extension Date”) and to allow the Company, without another stockholder vote, to elect to extend the Charter Extension Date to consummate an initial business combination on a monthly basis up to five times by an additional one month each time after September 20, 2023, upon the request by the Sponsor, and approval by the Company’s board of directors until February 20, 2024 or a total of up to eight months, unless the closing of an initial business combination shall have occurred prior thereto and (ii) delete (a) the limitation that the Company shall not consummate an initial business combination if it would cause the Company’s net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (or any successor rule)) to be less than $5,000,0001 following such redemptions and (b) the limitation that the Company shall not redeem public shares that would cause the Company’s net tangible assets to be less than $5,000,001 following such redemptions (collectively, the “Charter Amendment”).   On February 15, 2024, the Company held a special meeting of stockholders (the “Second Special Meeting”). At the Second Special Meeting, a proposal to amend the Certificate of Incorporation to extend the Termination Date by which the Company must consummate a business combination from February 20, 2024 to December 20, 2024 (the date that is 36 months from the closing date of the IPO) (the “Termination Date”) was passed.   Trust Account   Following the closing of the IPO on December 20, 2021, $116,725,000 from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was deposited into the Trust Account. This amount was comprised of $10.15 per Unit for the 11,500,000 Units sold in the IPO. Following the closing of the IPO and the exercise of the underwriters’ full over-allotment option, $116,725,000 was held in the Trust Account and will only be invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act, which invest only in direct U.S. government treasury obligations. Pursuant to the trust agreement, the trustee is not permitted to invest in other securities or assets. By restricting the investment of the proceeds to these instruments, and by having a business plan targeted at acquiring and growing businesses for the long term (rather than buying and selling businesses in the manner of a merchant bank or private equity fund), the Company intends to avoid being deemed an “investment company” within the meaning of the Investment Company Act. The Trust Account is intended as a holding place for funds pending the earliest to occur of: (i) the consummation of the Company's initial business combination; (ii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend its amended and restated certificate of incorporation (A) to modify the substance or timing of its obligation to allow redemptions in connection with the Company's initial business combination or certain amendments to its charter prior thereto or to redeem 100% of the Company's public shares if the Company does not consummate its initial business combination by the Termination Date or (B) with respect to any other provision relating to stockholders' rights or pre-initial business combination activity; or (iii) absent an initial business combination by the Termination Date, the Company's return of the funds held in the Trust Account to its public stockholders as part of its redemption of the public shares.   If the Company is unable to consummate its initial business combination, the Company's public stockholders may receive only approximately $10.35 per public share on the liquidation of the Trust Account and its Public Warrants will expire worthless.   The Company will provide holders (the “Public Stockholders”) of its common stock sold in the IPO (the “Public Shares”), with the opportunity to redeem all or a portion of their Public Shares upon the completion of a business combination either (i) in connection with a general meeting called to approve the business combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed business combination or conduct a tender offer will be made by the Company, solely at its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek stockholder approval under applicable law or stock exchange listing requirement.   The Company will provide its Public Stockholders with the opportunity to redeem all or a portion of their common stock upon the completion of the initial business combination, regardless of whether such stockholder votes on such proposed business combination, and if they do vote, regardless of whether they vote for or against such proposed business combination, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial business combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then-outstanding public shares, subject to the limitations described herein. The amount in the Trust Account is currently anticipated to be $10.35 per public share.   The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters. The redemption rights will include the requirement that a beneficial holder must identify itself in order to validly redeem its shares. There will be no redemption rights upon the completion of the initial business combination with respect to the Company’s warrants. Further, the Company will not proceed with redeeming the Public Shares, even if a Public Stockholders has properly elected to redeem its shares if a business combination does not close.    All common stock subject to redemption was recorded at a redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity (“ASC Topic 480”). The Company will proceed with a business combination if the Company seeks stockholder approval and a majority of the issued and outstanding shares cast are voted in favor of the business combination. Following the Second Special Meeting, the Company’s Certificate of Incorporation provides that the Company will have until the Termination Date to consummate its initial business combination. If the Company has not consummated an initial business combination by the Termination Date, the Company will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income taxes, if any (less up to $50,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably practicable following such redemption, subject to the approval of the Company’s remaining stockholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to consummate an initial business combination by the Termination Date.   The Sponsor and each member of its management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares (defined in Note 7), Private Placement Warrants and Public Shares held by them (ii) to waive their redemption rights with respect to their Founder Shares, Private Placement Warrants and Public Shares in connection with a stockholder vote to approve an amendment to the Company’s Certificate of Incorporation (A) that would modify the substance or timing of the Company’s obligation to provide holders of shares of common stock the right to have their shares redeemed in connection with the initial business combination or to redeem 100% of the public shares if the Company does not complete the initial business combination by the Termination Date or (B) with respect to any other provision relating to the rights of holders of shares of common stock or pre-initial business combination activity and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares and Private Placement Warrants they hold if the Company fails to consummate an initial business combination by the Termination Date (although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete the initial business combination within the prescribed time frame).   The Sponsor has agreed to waive its liquidation rights with respect to the Founder Shares and Private Placement Warrants if the Company fails to consummate a business combination by the Termination Date. However, if the Sponsor acquires Public Shares in or after the Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to consummate a business combination by the Termination Date. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) in the event the Company does not consummate a business combination by the Termination Date and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Public Offering price per Unit ($10.35 per Public Share).    In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written confidentiality or similar agreement, letter of intent, or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (1) $10.35 per public share, and (2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay the Company’s taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses, or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.   Merger Agreement   On June 23, 2024, ADRT entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) by and among ADRT, ADRT Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of ADRT (“Merger Sub”), and Gresham Worldwide, Inc., a California corporation (“Gresham”). The transactions contemplated by the Merger Agreement are referred to herein as the “Business Combination.”   Pursuant to the Merger Agreement and subject to the terms and conditions set forth therein, the Merger Sub was intended to merge with and into Gresham (the “Merger”), with Gresham being the surviving corporation and thereby becoming a wholly owned subsidiary of ADRT. Upon the Closing of the Business Combination (the “Effective Time”), it was expected that ADRT would be renamed Gresham Worldwide, Inc., and thereafter remain listed on the NYSE American under a new ticker symbol, “GWWI.”   While each of ADRT and Gresham is a publicly traded corporation, Ault beneficially owns a majority of each of ADRT’s and Gresham’s shares of common stock and the Boards of Directors of Ault, ADRT and Gresham consist of several identical members. As such, the Business Combination is a related party transaction.   The Merger Agreement and the transactions contemplated thereby were unanimously approved by the board of directors of ADRT and Gresham. The Business Combination was targeted to be consummated in the fourth quarter of 2024, after receipt of the required approval by the stockholders of ADRT, the required approval of the shareholders of Gresham and the fulfilment of certain other terms and conditions set forth in the Merger Agreement.   However, on August 14, 2024, Gresham filed a petition for reorganization under Chapter XI of the bankruptcy laws. Consequently, ADRT was required to terminate the Merger Agreement, which it did on August 15, 2024.  It is uncertain whether we will enter into a new agreement and plan of merger with a third party. Liquidity and Going Concern   As of June 30, 2024, the Company had cash of $866 held outside of the Trust Account and a working capital deficit of $2,615,493. As of June 30, 2024, the Company had marketable securities held in the Trust Account of approximately $794,122, consisting of U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended, which invest only in direct U.S. government treasury obligations. Investment and interest income on the balance in the Trust Account may be used by the Company to pay taxes. During the three months and six months ended June 30, 2024, $10,219 and $31,182, respectively, of income from investments held in the Trust Account was earned.    In order to finance transaction costs in connection with the initial business combination, our Sponsor or an affiliate of the Sponsor, or certain of our officers and directors may, but are not obligated to, provide us with funds as may be required (“Working Capital Loans”). We may need to raise additional capital through loans or additional investments from our Sponsor, stockholders, officers, directors, or third parties. Our officers, directors and our Sponsor may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet our working capital needs. Accordingly, we may not be able to obtain additional financing. If we are unable to raise additional capital, we may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. We cannot provide any assurance that new financing will be available to us on commercially acceptable terms, if at all. We will provide our public stockholders with the opportunity to redeem all or a portion of their shares of our common stock upon the consummation of our initial business combination, subject to the limitations described herein.   It is uncertain whether we will be able to consummate an initial business combination by December 20, 2024 or obtain working capital loans from the Sponsor. If an initial business combination is not consummated by the required date pursuant to the rules of the NYSE American, there will be a mandatory liquidation and subsequent dissolution, presuming that the Company remains listed on the NYSE American. In the event of a dissolution, we anticipate a shortfall of liquidity. Our anticipated shortfall of sufficient liquidity to meet our current and future estimated financial obligations raises substantial doubt about our ability to continue as a going concern for a period of time within one year after the date that the accompanying financial statements are issued. We plan to address this uncertainty through working capital loans. There is no assurance that working capital loans will be available to us or that any plans to consummate an initial business combination will be successful.   Risks and Uncertainties   The Company has a limited operating history and has not yet generated revenue from intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including but not limited to, credit risk, changes to regulations governing the Company’s industry, and the outbreak or escalation of wars including, but not limited to, conflicts between Russia and Ukraine and between Israel and Hamas and other groups or states in the region, and the relationship between China and the U.S. Adverse developments in these general business and economic conditions could have a material adverse effect on the Company’s financial condition and the results of its operations.   Inflation Reduction Act of 2022   On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its stockholder from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.   On December 27, 2022, the Treasury released Notice 2023-2, which provides taxpayers with interim guidance on the excise tax that may be relied upon until the Internal Revenue Service issues proposed Treasury regulations on such matter. Notice 2023-2 includes as one of its exceptions to the excise tax a distribution in complete liquidation of a “covered corporation”, such as ours, to which Sec. 331 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), applies (so long as Sec. 332(a) of the Code also does not also apply). Although it remains uncertain whether, and/or to what extent, the excise tax could apply to any redemptions of our public shares after December 31, 2022, including any redemptions in connection with our initial business combination or in the event we do not consummate our initial business combination by the Termination Date, we would not expect the excise tax to apply to redemptions of our public shares that occur during a taxable year in which we completely liquidate under Sec. 331 of the Code.   Any redemption or other repurchase that occurs after December 31, 2022 may be subject to the excise tax, including in connection with our initial business combination, certain amendments to our charter or otherwise. Whether and to what extent we would be subject to the excise tax would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the initial business combination, certain amendments to our charter or otherwise, (ii) the structure of the initial business combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with the initial business combination (or otherwise issued not in connection with the initial business combination but issued within the same taxable year of the initial business combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by us and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete our initial business combination and in our ability to complete our initial business combination. As of December 31, 2023, we recognized approximately $1,200,638 in excise tax payable related to share redemptions. During the three months ended March 31, 2024, we recognized an additional $14,268 in excise tax payable related to share redemptions of 121,695 shares. As of June 30, 2024, the Company has recognized $1,214,906 in excise tax payable.

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2 — Basis of Presentation and Summary of Significant Accounting Policies   Basis of Presentation   The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).    Emerging Growth Company Status   The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.    Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non- emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.     Use of Estimates   The preparation of the financial statements is in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.   Common Stock Subject to Redemption   The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480. Common stock subject to mandatory redemption (if any) will be classified as a liability instrument and measured at fair value. Conditionally redeemable shares of common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) will be classified as temporary equity. At all other times shares of common stock will be classified as stockholders’ equity. The Company’s common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, 67,180 shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet at June 30, 2024.   The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of the shares of common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable shares of common stock are affected by charges against additional paid in capital or accumulated deficit if additional paid in capital is zero.   As of June 30, 2024 and December 31, 2023, the shares of common stock reflected in the condensed balance sheets are reconciled in the following table:         Common stock subject to possible redemption as of December 31, 2023   $ 2,201,557   Less:         Redemptions of common stock     (1,426,814 )  Plus:         Remeasurement of carrying value to redemption value     15,145   Common stock subject to possible redemption as of March 31, 2024     789,888   Plus:         Remeasurement of carrying value to redemption value     4,957   Common stock subject to possible redemption as of June 30, 2024     $ 794,845     Cash and Cash Equivalents   The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $866 and $163,235 in cash and no cash equivalents as of June 30, 2024 and December 31, 2023, respectively. As of June 30, 2024, there were no amounts yet to be remitted to tax authorities. As of December 31, 2023, $157,339 had yet to be remitted to tax authorities.   Marketable Securities Held in the Trust Account   At June 30, 2024 and December 31, 2023, funds held in the Trust Account included $794,122 and $2,200,308, respectively, of investments held in a money market fund characterized as Level 1 investments within the fair value hierarchy under ASC Topic 820 (as defined below). The funds were invested in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.   Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts.   Fair Value of Financial Instruments   The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC Topic 820, Fair Value Measurements and Disclosures (“ASC Topic 820”), approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.   Offering Costs Associated with the IPO   The Company complies with the requirements of ASC Topic 340-10-S99-1, Other Assets and Deferred Costs, and SEC Staff Accounting Bulletin (“SAB”) Topic 5A, Expenses of Offering. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the IPO. Offering costs associated with warrants and shares of common stock not subject to redemption are charged to stockholders’ deficit. The Company incurred offering costs amounting to $6,297,333, consisting of $2,513,333 of underwriting commissions, $3,000,000 of deferred underwriting commissions, and $784,000 of other offering costs. The underwriters’ exercise of their full over-allotment option generated an additional $825,000 in transaction costs for aggregate transaction costs of $7,122,333, consisting of $2,888,333 of underwriting commissions, $3,450,000 of deferred underwriting commissions and $784,000 of other offering costs.   Warrant Instruments   The Company accounted for the 8,625,000 Public Warrants and the 9,400,000 Private Placement Warrants issued in connection with the IPO and Private Placement in accordance with the guidance contained in ASC Topic 480 and ASC Topic 815, Derivatives and Hedging, (“ASC Topic 815”). The assessment considered whether the instruments are freestanding financial instruments pursuant to ASC Topic 480, meet the definition of a liability pursuant to ASC Topic 480, or whether the instruments meet all of the requirements for equity classification under ASC Topic 815, including whether the instruments are indexed to the Company’s own common stock and whether the holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, as well as other conditions, for equity classification. The Public and Private Placement Warrants met the criteria for equity classification.    Net (Loss) Income per Share of Common Stock   We comply with the accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share. Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. Remeasurement associated with the redeemable shares of common stock is excluded from net loss per share as the redemption value approximates fair value. At June 30, 2024 and 2023, we did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into shares of common stock and then share in our earnings. As a result, diluted loss per share is the same as basic loss per share for the periods presented.   The following table reflects the calculation of basic and diluted net loss per common share:                                     For the Three Months Ended June 30, 2024     For the Six Months Ended June 30, 2024     Common Stock Subject to Redemption     Non- Redeemable Common Stock     Common Stock Subject to Redemption     Non- Redeemable Common Stock   Basic and diluted net loss per share of common stock                                 Numerator:                                 Allocation of net loss   $ (5,620 )   $ (240,532 )   $ (18,819 )   $ (537,044 ) Denominator:                                 Basic and diluted weighted average shares outstanding     67,180       2,875,000       101,281       2,875,000                                     Basic and diluted net loss per share of common stock   $ (0.08 )   $ (0.08 )   $ (0.19 )   $ (0.19 )   The following table reflects the calculation of basic and diluted net income per common share:       For the Three Months Ended June 30, 2023     For the Six Months Ended June 30, 2023     Common Stock Subject to Redemption     Non- Redeemable Common Stock     Common Stock Subject to Redemption     Non- Redeemable Common Stock   Basic and diluted net income per share of common stock                                 Numerator:                                 Allocation of net income   $ 412,467     $ 112,877     $ 857,023     $ 223,993   Denominator:                                 Basic and diluted weighted average shares outstanding     10,505,615       2,875,000       11,000,061       2,875,000                                     Basic and diluted net income per share of common stock   $ 0.04     $ 0.04     $ 0.08     $ 0.08     Income Taxes   The Company calculates its interim income tax provision in accordance with ASC Topic 270, Interim Reporting, and ASC Topic 740, Income Taxes (“ASC Topic 740”). The Company’s effective tax rate (“ETR”) from operations was 1.2% and 0.8% for the three and six months ended June 30, 2024, respectively, and 36% and 37% for the three and six months ended June 30, 2023, respectively. The Company recorded an income tax benefit of ($4,481) and ($4,723) for the three and six months ended June 30, 2024, respectively, and income tax expense of $298,033 and $636,876 for the three and six months ended June 30, 2023, respectively. The difference between the ETR and federal statutory rate of 21.0% is primarily attributable to a U.S. federal valuation allowance.   A valuation allowance is recorded when it is more-likely-than-not some of the Company’s deferred tax assets may not be realized. Significant judgment is applied when assessing the need for a valuation allowance and the Company considers future taxable income, reversals of existing deferred tax assets and liabilities and ongoing prudent and feasible tax planning strategies, in making such assessment. For the three and six months ended June 30, 2024, the valuation allowance was $780,858 and $678,364, respectively.   The Company records uncertain tax positions in accordance with ASC Topic 740 on the basis of a two-step process in which (i) the Company determines whether it is more likely than not a tax position will be sustained on the basis of the technical merits of such position and (ii) for those tax positions meeting the more-likely-than-not recognition threshold, the Company would recognize the largest amount of tax benefit that is more than 50.0% likely to be realized upon ultimate settlement with the related tax authority. The Company has determined it had no uncertain tax positions as of June 30, 2024 and 2023. The Company classifies interest and penalties recognized on uncertain tax positions as a component of income tax expense.   Recent Accounting Pronouncements   In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (ASC 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”), which clarifies that a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, ASU No. 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. The Company’s adoption of ASU 2202-03 did not have a material impact on its financial statements and disclosures.   In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires disclosure of incremental income tax information within the rate reconciliation and expanded disclosures of income taxes paid, among other disclosure requirements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company’s management does not believe the adoption of ASU 2023-09 will have a material impact on its financial statements and disclosures.   Management does not believe that any other recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Initial Public Offering	6 Months Ended
	Jun. 30, 2024
Initial Public Offering
Initial Public Offering	Note 3 — Initial Public Offering   On December 20, 2021, the Company consummated its IPO of 10,000,000 Units at a purchase price of $10.00 per Unit. Each Unit that the Company is offering has a price of $10.00 and consists of one share of common stock and three-fourths of one redeemable warrant. Each whole warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment (see Note 7). On December 20, 2021, the underwriters exercised their full over-allotment option and purchased the additional Units available to them. The aggregate Units sold in the IPO and subsequent over-allotment were 11,500,000 and generated gross proceeds of $115,000,000.    Following the closing of the IPO on December 20, 2021, $116,725,000 from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was deposited into the Trust Account. This amount was comprised of $10.15 per Unit for the 11,500,000 Units sold in the IPO. Following the closing of the IPO and the exercise of the underwriters’ full over-allotment option, $116,725,000 ($10.15 per Unit) was placed in the Trust Account and will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations.

Private Placement Warrants	6 Months Ended
	Jun. 30, 2024
Private Placement Warrants
Private Placement Warrants	Note 4 — Private Placement Warrants   Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 6,500,000 Private Placement Warrants (7,100,000 Private Placement Warrants when the underwriters’ over-allotment option was fully exercised on December 20, 2021), each exercisable to purchase one share of common stock at $11.50 per share, at a price of $1.00 per Private Placement Warrant. The sale of the Private Placement Warrants in connection with the IPO and subsequent over-allotment option exercise generated gross proceeds of $7,100,000. Additionally, 2,300,000 Private Placement Warrants were issued in relation to the extension payments, at a price of $1.00 per warrant, for an aggregate purchase price of $9,400,000. Each Private Placement Warrant is identical to the Public Warrants, except as described below. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Founder Shares, Private Placement Warrants or placement rights, which will expire worthless if the Company does not consummate the initial business combination by the Termination Date.   The Private Placement Warrants are not transferable, assignable or salable (and the shares of common stock issuable upon exercise of the Private Placement Warrants are not transferable, assignable or salable until 30 days after the completion of the initial business combination).   If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants are redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the Units sold in the Public Offering. Any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants requires a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants.

Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 5 — Related Party Transactions   Founder Shares   On February 23, 2021, the Company issued the Sponsor an aggregate of 2,875,000 shares of the Company’s common stock, par value $0.001 per share (the “Founder Shares”) for an aggregate purchase price of $25,000. The Sponsor has agreed, subject to certain limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) one year following the date of the consummation of the Company’s initial business combination or (B) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Public Stockholders having the right to exchange their shares of common stock for cash, securities or other property. Notwithstanding the foregoing, all Founder Shares will be released from the lock-up if (1) the last reported sale price of the Company’s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Company’s initial business combination or (2) if after a business combination there is a transaction whereby all of the Company’s stockholders have the right to exchange their shares for cash, securities or other property. The Sponsor did not transfer, assign or sell any of the Founder Shares during the six months ended June 30, 2024 or June 30, 2023.   Private Placement Warrants   The Sponsor purchased an aggregate of 9,400,000 Private Placement Warrants, which includes the purchase of 6,500,000 Private Placement Warrants simultaneously with the closing of the IPO, 600,000 Private Placement Warrants purchased by the Sponsor to account for the underwriters’ exercise of the over-allotment option, and 2,300,000 Private Placement Warrants issued in relation to the extension payments, at a price of $1.00 per warrant, for an aggregate purchase price of $9,400,000. Each Private Placement Warrant is identical to the Public Warrants, except as described below. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Founder Shares, Private Placement Warrants or placement rights, which will expire worthless if the Company does not consummate the initial business combination by the Termination Date.   Administrative Services Agreement   The Sponsor, through the earlier of the Company’s consummation of the initial business combination and its liquidation, makes available to the Company certain general and administrative services, including office space, utilities, and administrative services, as the Company may require from time to time. The Company has agreed to pay the Sponsor $10,000 per month for these services. The Company incurred $30,000 and $60,000 in operating cost associated with the administrative service fees for each of the three and six months ended June 30, 2024 and 2023, respectively.   Line of Credit   On June 30, 2023, we entered into a line of credit agreement (the “Line of Credit”) with Ault, which was subsequently amended twice, effective as of December 15, 2023 and March 5, 2024, which bears interest at 9.5% per annum. The Line of Credit agreement is for 18 months (unless a credit extension is granted by Ault) and provides for up to an aggregate of $1,200,000 of advances from the Sponsor under a promissory note. As of June 30, 2024, we had an outstanding principal advance balance of $950,681 and accrued interest of $37,871 under the Line of Credit agreement. The outstanding principal balance of the promissory note will become due and payable five business days after written demand for repayment is made by Ault. We can prepay any advances without penalty or premium upon notice. If any payment is not made within ten (10) days after the date such payment is due, we shall pay Ault a late fee equal to the lesser of (i) five percent (5%) of the amount of such unpaid amount or (ii) the maximum amount permitted to be charged under applicable law. As of the date of this report, we have not received a demand for repayment from Ault.

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments
Commitments and Contingencies	Note 6 — Commitments and Contingencies   Registration and Stockholder Rights   The holders of the Founder Shares, Public Warrants and Private Placement Warrants that may be issued upon conversion of Working Capital Loans (and any shares of common stock issuable upon the exercise of the Private Placement Warrants, including those issued upon conversion of the working capital loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement signed on the effective date of the IPO requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to shares of common stock). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of the initial business combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that no sales of these securities will be effected until after the expiration of the applicable lock-up period, as described herein. The Company will bear the expenses incurred in connection with the filing of any such registration statements.   Underwriting Agreement   The underwriters had a 45-day option from the date of the IPO to purchase up to an additional 1,500,000 Units to cover over-allotments, if any. On December 20, 2021, the underwriters fully exercised the over-allotment option.    The underwriters were paid at the closing of the IPO an underwriting commission of $0.25 per Unit sold in the IPO or $2,513,333. Following the exercise of the underwriters’ over-allotment option on December 20, 2021, the underwriters earned an additional $375,000 for an aggregate of $2,888,333 in underwriting commissions related to the IPO and over-allotment.   In addition, $3,000,000 is payable to the underwriters for deferred underwriting commissions related to the Units sold in the IPO. Following the exercise of the underwriters’ over-allotment option on December 20, 2021, the underwriters earned an additional $450,000 for an aggregate of $3,450,000 in deferred underwriting commissions related to the IPO and over-allotment. The deferred underwriting commission will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a business combination, subject to the terms of the underwriting agreement.    Excise Tax   In connection with the votes to approve the Charter Amendment, 11,311,125 shares of common stock of the Company were tendered for redemption at a per-share price of $10.61 for an aggregate redemption amount of approximately $120,063,828. As such, the Company has recorded a 1% excise tax liability in the amount of $1,200,638 on the balance sheet as of December 31, 2023. This excise tax liability can be offset by future share issuances within the same fiscal year which will be evaluated and adjusted in the period in which the issuances occur.   In connection with the Second Special Meeting, the Company redeemed 121,695 shares from its public stockholders at a redemption price of approximately $11.61 per share. There are 2,942,180 non-redeemed shares remaining as of the date of this quarterly report, of which 2,875,000 are held by the Sponsor. During the three months ended March 31, 2024, we recognized an additional $14,268 in excise tax payable related to share redemptions of 121,695 shares. As of June 30, 2024, the Company has recognized $1,214,906 in excise tax payable.

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Stockholders’ Equity	Note 7 — Stockholders’ Equity   Preferred Stock   The Company is authorized to issue 1,000,000 preferred shares with a par value of $0.001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2024 and December 31, 2023, there were no preferred shares issued or outstanding.    Common Stock   The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.001 per share. As of June 30, 2024 and December 31, 2023, there were 2,875,000 shares of common stock outstanding, excluding 67,180 and 188,875 shares of common stock subject to possible redemption issued, respectively.   Founder Shares   On February 23, 2021, the Sponsor purchased 2,875,000 Founder Shares for an aggregate price of $25,000.   The Sponsor agreed, subject to certain limited exceptions, not to transfer, assign or sell their Founder Shares, for a period ending on the date that is the earlier of (A) one year following the date of the consummation of the Company’s initial business combination or (B) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Public Stockholders having the right to exchange their shares of common stock for cash, securities or other property. Notwithstanding the foregoing, all Founder Shares will be released from the lock-up if (1) the last reported sale price of the Company’s common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Company’s initial business combination or (2) if after a business combination there is a transaction whereby all of the Company’s stockholders have the right to exchange their shares for cash, securities or other property.   Public Warrants and Private Placement Warrants   Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants were issued upon separation of the Units and only whole Public Warrants trade. The Public Warrants will become exercisable on the later of (a) one year after the date that the registration statement for the offering is declared effective by the SEC and (b) the consummation of a business combination; provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available.   The Public Warrants have an exercise price of $11.50 per share, subject to adjustment as described herein. In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the consummation of the Company’s initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial business combination on the date of the consummation of the Company’s initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial business combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price.   If a registration statement covering the issuance of the shares of common stock issuable upon exercise of the warrants is not effective by the 60th business day following the consummation of the Company’s initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.   Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants):   • in whole and not in part;   • at a price of $0.01 per warrant;   • upon not less than 30 days’ prior written notice of redemption given after the warrants become exercisable (the “30-day redemption period”) to each warrant holder; and   • if, and only if, the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending three days before the Company sends the notice of redemption to the warrant holders.   The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the shares of common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of common stock is available throughout the 30-day redemption period, except if the warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act. If and when the warrants become redeemable by the Company, the Company may not exercise its redemption right if the issuance of shares of common stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or the Company is unable to effect such registration or qualification. The Company will use its best efforts to register or qualify such shares of common stock under the blue sky laws of the state of residence in those states in which the warrants were offered by the Company in the Public Offering.   If the Company calls the warrants for redemption as described above, the Company’s management will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In determining whether to require all holders to exercise their warrants on a “cashless basis,” the Company’s management will consider, among other factors, its cash position, the number of outstanding warrants and the dilutive effect on the Company’s stockholders of issuing the maximum number of shares of common stock issuable upon the exercise of the Company’s warrants. In such an event, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” for this purpose shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.   The Sponsor purchased an aggregate of 9,400,000 Private Placement Warrants, which includes the purchase of 6,500,000 Private Placement Warrants simultaneously with the closing of the IPO, 600,000 Private Placement Warrants purchased by the Sponsor to account for the underwriters’ exercise of the over-allotment option, and 2,300,000 Private Placement Warrants issued in relation to the extension payments, at a price of $1.00 per warrant, for an aggregate purchase price of $9,400,000. Each Private Placement Warrant is identical to the Public Warrants, except as described below. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Founder Shares, Private Placement Warrants or placement rights, which will expire worthless if the Company does not consummate the initial business combination by the Termination Date.   All warrants relating to the IPO are financial instruments that are classified as equity in accordance with ASC Topic 815.   NYSE Regulation Notice of Noncompliance   On July 19, 2023, the Company received a letter (the “Letter”) from the staff of NYSE of the New York Stock Exchange (“NYSE”) indicating that the Company is not currently in compliance with (i) Section 1003(b)(i)(A) of the NYSE American LLC (“NYSE American”) Company Guide (the “Company Guide”), which requires the Company to maintain a minimum of 200,000 shares publicly held on a continuous basis (the “Minimum Public Float”), and (ii) Section 1003(b)(i)(B) of the Company Guide, which requires the Company to maintain a minimum of 300 public stockholders on a continuous basis (the “Minimum Public Holders”).   On August 18, 2023, the Company submitted a plan of compliance (the “Plan”) to the NYSE American addressing how it intends to regain compliance with these requirements by December 15, 2024. On September 27, 2023, the Company received notice from the NYSE American that it had accepted the Plan and granted a Plan period until December 15, 2024, in order to regain compliance. The Company’s progress toward regaining compliance is subject to periodic review by the NYSE American, including quarterly monitoring for compliance with the initiatives outlined in the Plan. However, there can be no assurance that the Company will be able to satisfy the NYSE American’s continued listing requirements, regain compliance with the Minimum Public Float and Minimum Public Holders requirements, or maintain compliance with the other listing requirements.

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8 — Fair Value Measurements   Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:   ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;   ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and   ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.   The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:                                     June 30,     Quoted Prices In Active Markets     Significant Other Observable Inputs     Significant Other Unobservable Inputs       2024     (Level 1)     (Level 2)     (Level 3)   Description                                 Assets:                                 U.S. Money Market Funds held in the Trust Account   $ 794,112     $ 794,112     $ -     $ -   Total   $ 794,112     $ 794,112     $ -     $ -         December 31,     Quoted Prices In Active Markets     Significant Other Observable Inputs     Significant Other Unobservable Inputs       2023     (Level 1)     (Level 2)     (Level 3)   Description                                 Assets:                                 U.S. Money Market Funds held in the Trust Account   $ 2,200,308     $ 2,200,308     $ -     $ -   Total   $ 2,200,308     $ 2,200,308     $ -     $ -     There were no transfers between Levels 1, 2 or 3 during the six months ended June 30, 2024 and the fiscal year ended December 31, 2023.

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 9 — Subsequent Events    The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date that the financial statements were issued. Based on this, other than those discussed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation   The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).
Emerging Growth Company Status	Emerging Growth Company Status   The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.    Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non- emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates   The preparation of the financial statements is in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Common Stock Subject to Redemption	Common Stock Subject to Redemption   The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480. Common stock subject to mandatory redemption (if any) will be classified as a liability instrument and measured at fair value. Conditionally redeemable shares of common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) will be classified as temporary equity. At all other times shares of common stock will be classified as stockholders’ equity. The Company’s common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, 67,180 shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet at June 30, 2024.   The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of the shares of common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable shares of common stock are affected by charges against additional paid in capital or accumulated deficit if additional paid in capital is zero.   As of June 30, 2024 and December 31, 2023, the shares of common stock reflected in the condensed balance sheets are reconciled in the following table:         Common stock subject to possible redemption as of December 31, 2023   $ 2,201,557   Less:         Redemptions of common stock     (1,426,814 )  Plus:         Remeasurement of carrying value to redemption value     15,145   Common stock subject to possible redemption as of March 31, 2024     789,888   Plus:         Remeasurement of carrying value to redemption value     4,957   Common stock subject to possible redemption as of June 30, 2024     $ 794,845
Cash and Cash Equivalents	Cash and Cash Equivalents   The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $866 and $163,235 in cash and no cash equivalents as of June 30, 2024 and December 31, 2023, respectively. As of June 30, 2024, there were no amounts yet to be remitted to tax authorities. As of December 31, 2023, $157,339 had yet to be remitted to tax authorities.
Marketable Securities Held in the Trust Account	Marketable Securities Held in the Trust Account   At June 30, 2024 and December 31, 2023, funds held in the Trust Account included $794,122 and $2,200,308, respectively, of investments held in a money market fund characterized as Level 1 investments within the fair value hierarchy under ASC Topic 820 (as defined below). The funds were invested in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Concentration of Credit Risk	Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts.
Fair Value of Financial Instruments	Fair Value of Financial Instruments   The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC Topic 820, Fair Value Measurements and Disclosures (“ASC Topic 820”), approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature.
Offering Costs Associated with the IPO	Offering Costs Associated with the IPO   The Company complies with the requirements of ASC Topic 340-10-S99-1, Other Assets and Deferred Costs, and SEC Staff Accounting Bulletin (“SAB”) Topic 5A, Expenses of Offering. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the IPO. Offering costs associated with warrants and shares of common stock not subject to redemption are charged to stockholders’ deficit. The Company incurred offering costs amounting to $6,297,333, consisting of $2,513,333 of underwriting commissions, $3,000,000 of deferred underwriting commissions, and $784,000 of other offering costs. The underwriters’ exercise of their full over-allotment option generated an additional $825,000 in transaction costs for aggregate transaction costs of $7,122,333, consisting of $2,888,333 of underwriting commissions, $3,450,000 of deferred underwriting commissions and $784,000 of other offering costs.
Warrant Instruments	Warrant Instruments   The Company accounted for the 8,625,000 Public Warrants and the 9,400,000 Private Placement Warrants issued in connection with the IPO and Private Placement in accordance with the guidance contained in ASC Topic 480 and ASC Topic 815, Derivatives and Hedging, (“ASC Topic 815”). The assessment considered whether the instruments are freestanding financial instruments pursuant to ASC Topic 480, meet the definition of a liability pursuant to ASC Topic 480, or whether the instruments meet all of the requirements for equity classification under ASC Topic 815, including whether the instruments are indexed to the Company’s own common stock and whether the holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, as well as other conditions, for equity classification. The Public and Private Placement Warrants met the criteria for equity classification.
Net (Loss) Income per Share of Common Stock	Net (Loss) Income per Share of Common Stock   We comply with the accounting and disclosure requirements of FASB ASC Topic 260, Earnings Per Share. Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. Remeasurement associated with the redeemable shares of common stock is excluded from net loss per share as the redemption value approximates fair value. At June 30, 2024 and 2023, we did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into shares of common stock and then share in our earnings. As a result, diluted loss per share is the same as basic loss per share for the periods presented.   The following table reflects the calculation of basic and diluted net loss per common share:                                     For the Three Months Ended June 30, 2024     For the Six Months Ended June 30, 2024     Common Stock Subject to Redemption     Non- Redeemable Common Stock     Common Stock Subject to Redemption     Non- Redeemable Common Stock   Basic and diluted net loss per share of common stock                                 Numerator:                                 Allocation of net loss   $ (5,620 )   $ (240,532 )   $ (18,819 )   $ (537,044 ) Denominator:                                 Basic and diluted weighted average shares outstanding     67,180       2,875,000       101,281       2,875,000                                     Basic and diluted net loss per share of common stock   $ (0.08 )   $ (0.08 )   $ (0.19 )   $ (0.19 )   The following table reflects the calculation of basic and diluted net income per common share:       For the Three Months Ended June 30, 2023     For the Six Months Ended June 30, 2023     Common Stock Subject to Redemption     Non- Redeemable Common Stock     Common Stock Subject to Redemption     Non- Redeemable Common Stock   Basic and diluted net income per share of common stock                                 Numerator:                                 Allocation of net income   $ 412,467     $ 112,877     $ 857,023     $ 223,993   Denominator:                                 Basic and diluted weighted average shares outstanding     10,505,615       2,875,000       11,000,061       2,875,000                                     Basic and diluted net income per share of common stock   $ 0.04     $ 0.04     $ 0.08     $ 0.08
Income Taxes	Income Taxes   The Company calculates its interim income tax provision in accordance with ASC Topic 270, Interim Reporting, and ASC Topic 740, Income Taxes (“ASC Topic 740”). The Company’s effective tax rate (“ETR”) from operations was 1.2% and 0.8% for the three and six months ended June 30, 2024, respectively, and 36% and 37% for the three and six months ended June 30, 2023, respectively. The Company recorded an income tax benefit of ($4,481) and ($4,723) for the three and six months ended June 30, 2024, respectively, and income tax expense of $298,033 and $636,876 for the three and six months ended June 30, 2023, respectively. The difference between the ETR and federal statutory rate of 21.0% is primarily attributable to a U.S. federal valuation allowance.   A valuation allowance is recorded when it is more-likely-than-not some of the Company’s deferred tax assets may not be realized. Significant judgment is applied when assessing the need for a valuation allowance and the Company considers future taxable income, reversals of existing deferred tax assets and liabilities and ongoing prudent and feasible tax planning strategies, in making such assessment. For the three and six months ended June 30, 2024, the valuation allowance was $780,858 and $678,364, respectively.   The Company records uncertain tax positions in accordance with ASC Topic 740 on the basis of a two-step process in which (i) the Company determines whether it is more likely than not a tax position will be sustained on the basis of the technical merits of such position and (ii) for those tax positions meeting the more-likely-than-not recognition threshold, the Company would recognize the largest amount of tax benefit that is more than 50.0% likely to be realized upon ultimate settlement with the related tax authority. The Company has determined it had no uncertain tax positions as of June 30, 2024 and 2023. The Company classifies interest and penalties recognized on uncertain tax positions as a component of income tax expense.
Recent Accounting Pronouncements	Recent Accounting Pronouncements   In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (ASC 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”), which clarifies that a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, ASU No. 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. The Company’s adoption of ASU 2202-03 did not have a material impact on its financial statements and disclosures.   In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires disclosure of incremental income tax information within the rate reconciliation and expanded disclosures of income taxes paid, among other disclosure requirements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company’s management does not believe the adoption of ASU 2023-09 will have a material impact on its financial statements and disclosures.   Management does not believe that any other recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of common stock subject to possible redemption	Common stock subject to possible redemption as of December 31, 2023   $ 2,201,557   Less:         Redemptions of common stock     (1,426,814 )  Plus:         Remeasurement of carrying value to redemption value     15,145   Common stock subject to possible redemption as of March 31, 2024     789,888   Plus:         Remeasurement of carrying value to redemption value     4,957   Common stock subject to possible redemption as of June 30, 2024     $ 794,845
Schedule of reflects the calculation of basic and diluted	For the Three Months Ended June 30, 2024     For the Six Months Ended June 30, 2024     Common Stock Subject to Redemption     Non- Redeemable Common Stock     Common Stock Subject to Redemption     Non- Redeemable Common Stock   Basic and diluted net loss per share of common stock                                 Numerator:                                 Allocation of net loss   $ (5,620 )   $ (240,532 )   $ (18,819 )   $ (537,044 ) Denominator:                                 Basic and diluted weighted average shares outstanding     67,180       2,875,000       101,281       2,875,000                                     Basic and diluted net loss per share of common stock   $ (0.08 )   $ (0.08 )   $ (0.19 )   $ (0.19 )   The following table reflects the calculation of basic and diluted net income per common share:       For the Three Months Ended June 30, 2023     For the Six Months Ended June 30, 2023     Common Stock Subject to Redemption     Non- Redeemable Common Stock     Common Stock Subject to Redemption     Non- Redeemable Common Stock   Basic and diluted net income per share of common stock                                 Numerator:                                 Allocation of net income   $ 412,467     $ 112,877     $ 857,023     $ 223,993   Denominator:                                 Basic and diluted weighted average shares outstanding     10,505,615       2,875,000       11,000,061       2,875,000                                     Basic and diluted net income per share of common stock   $ 0.04     $ 0.04     $ 0.08     $ 0.08

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of fair value on a recurring basis	June 30,     Quoted Prices In Active Markets     Significant Other Observable Inputs     Significant Other Unobservable Inputs       2024     (Level 1)     (Level 2)     (Level 3)   Description                                 Assets:                                 U.S. Money Market Funds held in the Trust Account   $ 794,112     $ 794,112     $ -     $ -   Total   $ 794,112     $ 794,112     $ -     $ -         December 31,     Quoted Prices In Active Markets     Significant Other Observable Inputs     Significant Other Unobservable Inputs       2023     (Level 1)     (Level 2)     (Level 3)   Description                                 Assets:                                 U.S. Money Market Funds held in the Trust Account   $ 2,200,308     $ 2,200,308     $ -     $ -   Total   $ 2,200,308     $ 2,200,308     $ -     $ -

Organization and Business Operations (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 01, 2023	Dec. 13, 2022	Dec. 20, 2021	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2024	Dec. 31, 2023
Subsidiary, Sale of Stock [Line Items]
Deferred underwriting commissions				$ 3,450,000		$ 3,450,000	$ 3,450,000
Cash held from out side				1,849,679		1,849,679
Cash				866		866
Working Capital Amount				2,615,493		2,615,493
Marketable Securities				794,122		794,122
Investment Income, Net				10,219		31,182
Accrued excise tax				1,214,906		1,214,906	$ 1,200,638
Excise tax payable related to share redemptions					$ 14,268
Excise tax payable related to share redemptions, shares					121,695
Sponsor [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from option exercise						7,100,000
Deposit amount		$ 1,150,000
Payment for deposits	$ 2,331,995
Interest payment	$ 31,995
Number of warrants hold	9,400,000
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock to Sponsors (in shares)			10,000,000
Sale of stock, price per share			$ 10.00
Stock price per share			$ 11.50
Aggregate units sold in the IPO			$ 11,500,000
Gross proceeds			115,000,000
Transaction cost				6,297,333		6,297,333
Underwriting commissions				2,513,333		2,513,333
Deferred underwriting commissions			$ 3,000,000	3,000,000		3,000,000
Other offering costs				784,000		$ 784,000
Warrants upon consummation			6,500,000
Proceeds from issuance of common stock			$ 2,888,333
IPO [Member] | Sponsor [Member]
Subsidiary, Sale of Stock [Line Items]
No of warrants purchased						6,500,000
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock to Sponsors (in shares)			11,500,000
No of warrants purchased			2,300,000
Transaction cost				7,122,333		$ 7,122,333
Underwriting commissions				2,888,333		2,888,333
Deferred underwriting commissions				3,450,000		3,450,000
Other offering costs				784,000		784,000
Additional transaction cost				$ 825,000		$ 825,000
Payment for deposits			$ 2,300,000
Option exercised			600,000
Proceeds from issuance of common stock			$ 116,725,000
Over-Allotment Option [Member] | Sponsor [Member]
Subsidiary, Sale of Stock [Line Items]
No of warrants purchased			7,100,000			600,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, price per share			$ 10.15
Exercise price (in dollars per share)			$ 1.00
Private Placement [Member] | Sponsor [Member]
Subsidiary, Sale of Stock [Line Items]
No of warrants purchased						9,400,000
Exercise price (in dollars per share)				$ 1.00		$ 1.00
Warrants received	2,300,000	1,150,000
IPO and Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
No of warrants purchased						9,400,000
Proceeds from issuance of common stock			$ 116,725,000

Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024
Accounting Policies [Abstract]
Common stock subject to possible redemption, beginning	$ 789,888	$ 2,201,557
Redemption of common stock		(1,426,814)
Remeasurement of carrying value to redemption value	4,957	15,145
Common stock subject to possible redemption, ending	$ 794,845	$ 789,888

Basis of Presentation and Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Common Stock Subject to Mandatory Redemption [Member]
Allocation of net (loss) income	$ (5,620)	$ 412,467	$ (18,819)	$ 857,023
Basic weighted average shares outstanding	67,180	10,505,615	101,281	11,000,061
Diluted weighted average shares outstanding	67,180	10,505,615	101,281	11,000,061
Basic income (loss) per share	$ (0.08)	$ 0.04	$ (0.19)	$ 0.08
Diluted net income (loss) per share	$ (0.08)	$ 0.04	$ (0.19)	$ 0.08
Non Redeemable Common Stock [Member]
Allocation of net (loss) income	$ (240,532)	$ 112,877	$ (537,044)	$ 223,993
Basic weighted average shares outstanding	2,875,000	2,875,000	2,875,000	2,875,000
Diluted weighted average shares outstanding	2,875,000	2,875,000	2,875,000	2,875,000
Basic income (loss) per share	$ (0.08)	$ 0.04	$ (0.19)	$ 0.08
Diluted net income (loss) per share	$ (0.08)	$ 0.04	$ (0.19)	$ 0.08

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 20, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized redemption		67,180		67,180		188,875
Cash		$ 866		$ 866		$ 163,235
Cash equivalents		0		0		0
Tax authorities		0		0		157,339
Assets held-in-trust, noncurrent		794,122		794,122		2,200,308
Cash, fdic insured amount		250,000		250,000
Deferred underwriting commissions		$ 3,450,000		$ 3,450,000		3,450,000
Efective tax rate from continuing operations		1.20%	36.00%	0.80%	37.00%
Provision for income taxes		$ (4,481)	$ 298,033	$ (4,723)	$ 636,876
Valuation allowance		780,858		678,364
Unrecognized tax benefits		0		0		$ 0
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Business Acquisition, Transaction Costs		6,297,333		6,297,333
Underwriting commissions		2,513,333		2,513,333
Deferred underwriting commissions	$ 3,000,000	3,000,000		3,000,000
Other Ownership Interests, Offering Costs		784,000		784,000
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Business Acquisition, Transaction Costs		7,122,333		7,122,333
Underwriting commissions		2,888,333		2,888,333
Deferred underwriting commissions		3,450,000		3,450,000
Other Ownership Interests, Offering Costs		784,000		784,000
Additional transaction cost		$ 825,000		$ 825,000
No of warrants purchased	2,300,000
IPO and Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
No of warrants purchased				9,400,000

Initial Public Offering (Details Narrative)	1 Months Ended
	Dec. 20, 2021 USD ($) $ / shares shares
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued during period, shares, new issues | shares	10,000,000
Shares purchase price (in dollars per share) | $ / shares	$ 10.00
Sale of stock, description of transaction	Each Unit that the Company is offering has a price of $10.00 and consists of one share of common stock and three-fourths of one redeemable warrant.
Stock price per share | $ / shares	$ 11.50
Aggregate units sold in the IPO	$ 11,500,000
Proceeds from issuance of common stock	2,888,333
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock to sponsors (in value)	115,000,000
Proceeds from issuance of common stock	116,725,000
IPO and Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance of common stock	$ 116,725,000
Share price per unit | $ / shares	$ 10.15

Private Placement Warrants (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Dec. 20, 2021	Jun. 30, 2024	Jun. 01, 2023
Defined Benefit Plan Disclosure [Line Items]
Share price			$ 10.61
Over-Allotment Option [Member]
Defined Benefit Plan Disclosure [Line Items]
No of warrants purchased	2,300,000
Private Placement [Member]
Defined Benefit Plan Disclosure [Line Items]
Share price	$ 11.50
Exercise price (in dollars per share)	$ 1.00
Sponsor [Member]
Defined Benefit Plan Disclosure [Line Items]
Proceeds from option exercised		$ 7,100,000
Aggregate purchase price		$ 9,400,000
Sponsor [Member] | IPO [Member]
Defined Benefit Plan Disclosure [Line Items]
No of warrants purchased		6,500,000
Sponsor [Member] | Over-Allotment Option [Member]
Defined Benefit Plan Disclosure [Line Items]
No of warrants purchased	7,100,000	600,000
Sponsor [Member] | Private Placement [Member]
Defined Benefit Plan Disclosure [Line Items]
No of warrants purchased		9,400,000
Exercise price (in dollars per share)		$ 1.00
Aggregate purchase price		$ 9,400,000
Sponsor [Member] | Private Placement Warrants [Member]
Defined Benefit Plan Disclosure [Line Items]
No of warrants purchased		2,300,000

Related Party Transactions (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 23, 2021	Dec. 20, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Common stock, par or stated value per share			$ 0.001		$ 0.001		$ 0.001
Common stock par or stated value per share	$ 12.00
Business combination, reason for business combinations					There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Founder Shares, Private Placement Warrants or placement rights, which will expire worthless if the Company does not consummate the initial business combination by the Termination Date.
Administrative Services Agreement [Member]
Related Party Transaction [Line Items]
Sponsor fees					$ 10,000
Administrative service fees			$ 30,000	$ 60,000	30,000	$ 60,000
Private Placement [Member]
Related Party Transaction [Line Items]
Exercise price (in dollars per share)		$ 1.00
Over-Allotment Option [Member]
Related Party Transaction [Line Items]
No of warrants purchased		2,300,000
Common Stock [Member]
Related Party Transaction [Line Items]
Common stock, par or stated value per share	$ 0.001
Sponsor [Member]
Related Party Transaction [Line Items]
Shares issued for services	2,875,000
Aggregate purchase price	$ 25,000
Value of warrants purchased					9,400,000
Advance from related party					$ 1,200,000
Sponsor [Member] | Private Placement [Member]
Related Party Transaction [Line Items]
No of warrants purchased					9,400,000
Exercise price (in dollars per share)			$ 1.00		$ 1.00
Value of warrants purchased					$ 9,400,000
Sponsor [Member] | Over-Allotment Option [Member]
Related Party Transaction [Line Items]
No of warrants purchased		7,100,000			600,000
Sponsor [Member] | Private Placement Warrants [Member]
Related Party Transaction [Line Items]
No of warrants purchased					2,300,000
Ault Alliance [Member]
Related Party Transaction [Line Items]
Line of credit interest rate					9.50%
Advance from related party					$ 950,681
Accrued interest			$ 37,871		$ 37,871

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended	6 Months Ended
	Jun. 01, 2023	Dec. 20, 2021	Mar. 31, 2024	Jun. 30, 2024	Dec. 31, 2023
Subsidiary, Sale of Stock [Line Items]
Deferred underwriting commisions				$ 3,450,000	$ 3,450,000
Number of common stock tendered for redemption	11,311,125
Share price	$ 10.61
Value of common stock tendered for redemption	$ 120,063,828
Excise tax liability	$ 1,200,638
Number of shares redeemed				121,695
Redemption price				$ 11.61
Excise tax payable related to share redemptions			$ 14,268
Excise tax payable related to share redemptions, shares			121,695
Accrued excise tax				$ 1,214,906	$ 1,200,638
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Additional IPO to purchase		1,500,000
Underwriting commission of unit sold (per share)		$ 0.25
Underwriting commission of Unit sold in the IPO Value		$ 2,513,333
Proceeds from issuance of common stock		2,888,333
Deferred underwriting commisions		3,000,000		$ 3,000,000
I P O And Over Allotment [Member]
Subsidiary, Sale of Stock [Line Items]
Deferred underwriting commisions		$ 3,450,000

Stockholders’ Equity (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Dec. 20, 2021	Jun. 30, 2024	Dec. 31, 2023	Feb. 23, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized		1,000,000	1,000,000
Preferred stock, par value		$ 0.001	$ 0.001
Preferred stock, shares issued		0	0
Preferred stock, shares outstanding		0	0
Common stock, shares, authorized		100,000,000	100,000,000
Common stock, par or stated value per share		$ 0.001	$ 0.001
Common stock, shares, outstanding		2,875,000	2,875,000
Common stock subject to possible redemption issued		67,180	188,875
Common stock, shares, issued		2,875,000	2,875,000
Common stock value		$ 2,875	$ 2,875	$ 25,000
Class of warrant or right, expense or revenue recognized		The Public Warrants have an exercise price of $11.50 per share, subject to adjustment as described herein. In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the consummation of the Company’s initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial business combination on the date of the consummation of the Company’s initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial business combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price.
Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price (in dollars per share)	$ 1.00
Over-Allotment Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
No of warrants purchased	2,300,000
Sponsor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Value of warrants purchased		$ 9,400,000
Sponsor [Member] | Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
No of warrants purchased		9,400,000
Exercise price (in dollars per share)		$ 1.00
Value of warrants purchased		$ 9,400,000
Sponsor [Member] | IPO [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
No of warrants purchased		6,500,000
Sponsor [Member] | Over-Allotment Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
No of warrants purchased	7,100,000	600,000
Accretion of Carrying Value to Redemption Value One
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares, issued				2,875,000

Fair Value Measurements (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 794,112	$ 2,200,308
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	794,112	2,200,308
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	794,112	2,200,308
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	794,112	2,200,308
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets

---